<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosbiol</journal-id>
<journal-title-group>
<journal-title>PLoS Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1544-9173</issn>
<issn pub-type="epub">1545-7885</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32353004</article-id>
<article-id pub-id-type="pmc">7217483</article-id>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717</article-id>
<article-id pub-id-type="publisher-id">PBIOLOGY-D-20-00469</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Organisms</subject>
<subj-group>
<subject>Eukaryota</subject>
<subj-group>
<subject>Animals</subject>
<subj-group>
<subject>Vertebrates</subject>
<subj-group>
<subject>Amniotes</subject>
<subj-group>
<subject>Mammals</subject>
<subj-group>
<subject>Rodents</subject>
<subj-group>
<subject>Mice</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Psychology</subject>
<subj-group>
<subject>Behavior</subject>
<subj-group>
<subject>Animal Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Social Sciences</subject>
<subj-group>
<subject>Psychology</subject>
<subj-group>
<subject>Behavior</subject>
<subj-group>
<subject>Animal Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Zoology</subject>
<subj-group>
<subject>Animal Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Nervous System</subject>
<subj-group>
<subject>Synapses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Nervous System</subject>
<subj-group>
<subject>Synapses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Physiology</subject>
<subj-group>
<subject>Electrophysiology</subject>
<subj-group>
<subject>Neurophysiology</subject>
<subj-group>
<subject>Synapses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Physiology</subject>
<subj-group>
<subject>Electrophysiology</subject>
<subj-group>
<subject>Neurophysiology</subject>
<subj-group>
<subject>Synapses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Neuroscience</subject>
<subj-group>
<subject>Neurophysiology</subject>
<subj-group>
<subject>Synapses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Animal Studies</subject>
<subj-group>
<subject>Experimental Organism Systems</subject>
<subj-group>
<subject>Model Organisms</subject>
<subj-group>
<subject>Xenopus</subject>
<subj-group>
<subject>Xenopus Oocytes</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Model Organisms</subject>
<subj-group>
<subject>Xenopus</subject>
<subj-group>
<subject>Xenopus Oocytes</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Animal Studies</subject>
<subj-group>
<subject>Experimental Organism Systems</subject>
<subj-group>
<subject>Animal Models</subject>
<subj-group>
<subject>Xenopus</subject>
<subj-group>
<subject>Xenopus Oocytes</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Organisms</subject>
<subj-group>
<subject>Eukaryota</subject>
<subj-group>
<subject>Animals</subject>
<subj-group>
<subject>Vertebrates</subject>
<subj-group>
<subject>Amphibians</subject>
<subj-group>
<subject>Frogs</subject>
<subj-group>
<subject>Xenopus</subject>
<subj-group>
<subject>Xenopus Oocytes</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Cell Biology</subject>
<subj-group>
<subject>Cellular Types</subject>
<subj-group>
<subject>Animal Cells</subject>
<subj-group>
<subject>Neurons</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Neuroscience</subject>
<subj-group>
<subject>Cellular Neuroscience</subject>
<subj-group>
<subject>Neurons</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Brain</subject>
<subj-group>
<subject>Hippocampus</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Brain</subject>
<subj-group>
<subject>Hippocampus</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Psychology</subject>
<subj-group>
<subject>Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Social Sciences</subject>
<subj-group>
<subject>Psychology</subject>
<subj-group>
<subject>Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice</article-title>
<alt-title alt-title-type="running-head">Early NMDAR alteration and correction in Grin<italic>2b<sup>+/C456Y</sup></italic> mice</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Shin</surname>
<given-names>Wangyong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0003-6957</contrib-id>
<name>
<surname>Kim</surname>
<given-names>Kyungdeok</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Serraz</surname>
<given-names>Benjamin</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cho</surname>
<given-names>Yi Sul</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6036-8996</contrib-id>
<name>
<surname>Kim</surname>
<given-names>Doyoun</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7136-5865</contrib-id>
<name>
<surname>Kang</surname>
<given-names>Muwon</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8047-1029</contrib-id>
<name>
<surname>Lee</surname>
<given-names>Eun-Jae</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Hyejin</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bae</surname>
<given-names>Yong Chul</given-names>
</name>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3681-4845</contrib-id>
<name>
<surname>Paoletti</surname>
<given-names>Pierre</given-names>
</name>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5518-6584</contrib-id>
<name>
<surname>Kim</surname>
<given-names>Eunjoon</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>Institut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, Université PSL, CNRS, INSERM, Paris, France</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>Department of Anatomy and Neurobiology, School of Dentistry, Kyungpook National University, Daegu, Korea</addr-line></aff>
<aff id="aff004"><label>4</label>
<addr-line>Center for Synaptic Brain Dysfunctions, Institute for Basic Science (IBS), Daejeon, Korea</addr-line></aff>
<aff id="aff005"><label>5</label>
<addr-line>Department of Neurology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Südhof</surname>
<given-names>Thomas C.</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>Stanford University School of Medicine, UNITED STATES</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email>kime@kaist.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>4</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>18</volume>
<issue>4</issue>
<elocation-id>e3000717</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>2</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Shin et al</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Shin et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pbio.3000717.pdf"></self-uri>
<abstract>
<p>Extensive evidence links <italic>Glutamate receptor</italic>, <italic>ionotropic</italic>, <italic>NMDA2B</italic> (<italic>GRIN2B</italic>), encoding the GluN2B/NR2B subunit of N-methyl-D-aspartate receptors (NMDARs), with various neurodevelopmental disorders, including autism spectrum disorders (ASDs), but the underlying mechanisms remain unclear. In addition, it remains unknown whether mutations in GluN2B, which starts to be expressed early in development, induces early pathophysiology that can be corrected by early treatments for long-lasting effects. We generated and characterized <italic>Grin2b</italic>-mutant mice that carry a heterozygous, ASD-risk C456Y mutation (<italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup>). In <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, GluN2B protein levels were strongly reduced in association with decreased hippocampal NMDAR currents and NMDAR-dependent long-term depression (LTD) but unaltered long-term potentiation, indicative of mutation-induced protein degradation and LTD sensitivity. Behaviorally, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice showed normal social interaction but exhibited abnormal anxiolytic-like behavior. Importantly, early, but not late, treatment of young <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice with the NMDAR agonist D-cycloserine rescued NMDAR currents and LTD in juvenile mice and improved anxiolytic-like behavior in adult mice. Therefore, GluN2B-C456Y haploinsufficiency decreases GluN2B protein levels, NMDAR-dependent LTD, and anxiety-like behavior, and early activation of NMDAR function has long-lasting effects on adult mouse behavior.</p>
</abstract>
<abstract abstract-type="toc">
<p>Mice that carry a heterozygous, autism spectrum disorder-risk C456Y mutation in the NMDA receptor (NMDAR) subunit GluN2B show decreased protein levels, hippocampal NMDAR currents, and NMDAR-dependent long-term depression and have abnormal anxiolytic-like behavior. Early, but not late, treatment of the young mice with the NMDAR agonist D-cycloserine rescues these phenotypes.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>Institute for Basic Science</institution>
</funding-source>
<award-id>IBS-R002-D1</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5518-6584</contrib-id>
<name>
<surname>Kim</surname>
<given-names>Eunjoon</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>European Research Council</institution>
</funding-source>
<award-id>ERC Advanced Grant #693021</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3681-4845</contrib-id>
<name>
<surname>Paoletti</surname>
<given-names>Pierre</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100005737</institution-id>
<institution>Université Pierre et Marie Curie</institution>
</institution-wrap>
</funding-source>
<award-id>UPMC Paris 6</award-id>
<principal-award-recipient>
<name>
<surname>Serraz</surname>
<given-names>Benjamin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution>National Research Foundation of Korea</institution>
</funding-source>
<award-id>NRF-2017R1A5A2015391</award-id>
<principal-award-recipient>
<name>
<surname>Bae</surname>
<given-names>Yong Chul</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by the European Research Council (ERC Advanced Grant #693021 to PP), the University Pierre-et-Marie-Curie (UPMC Paris 6) and the Fondation pour la Recherche Médicale (FRM) (fellowships to BS), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT, NRF-2017R1A5A2015391 to YCB), and the Institute for Basic Science (IBS-R002-D1 to EK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="0"></table-count>
<page-count count="28"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2020-05-12</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All relevant data are within the paper and its Supporting Information files.</p>
</notes>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by social deficits and repetitive behaviors. Although a large number of ASD-risk mutations have been reported [<xref ref-type="bibr" rid="pbio.3000717.ref001">1</xref>], the mechanisms underlying ASD remain largely unclear. An emerging ASD-related mechanism is dysfunction of N-methyl-D-aspartate (NMDA) receptors (NMDARs) [<xref ref-type="bibr" rid="pbio.3000717.ref002">2</xref>], a key, multisubunit regulator of brain development and function that is subject to various forms of receptor modulation [<xref ref-type="bibr" rid="pbio.3000717.ref003">3</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref007">7</xref>]. Many known ASD-risk genetic variants have been shown to cause NMDAR dysfunction in animal models of ASD [<xref ref-type="bibr" rid="pbio.3000717.ref002">2</xref>] that are causally associated with ASD-like abnormal behaviors [<xref ref-type="bibr" rid="pbio.3000717.ref008">8</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref010">10</xref>]. However, a better animal model of ASD for the NMDAR dysfunction hypothesis would presumably be one carrying mutations in <italic>Glutamate receptor</italic>, <italic>ionotropic</italic>, <italic>NMDA1</italic> (<italic>GRIN1</italic>); <italic>GRIN2A</italic>; or <italic>GRIN2B</italic> genes encoding the main NMDAR subunits GluN1/NR1, GluN2A/NR2A, and GluN2B/NR2B, respectively.</p>
<p>Among known NMDAR subunit genes, <italic>GRIN2B</italic> is one of the most frequently mutated ASD-risk genes, belonging to category 1 in the Simons Foundation Autism Research Initiative (SFARI) gene list, and shows stronger impacts on ASD than mutations in <italic>GRIN1</italic> or <italic>GRIN2A</italic> [<xref ref-type="bibr" rid="pbio.3000717.ref001">1</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref011">11</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref016">16</xref>]. In addition to ASD, <italic>GRIN2B</italic> has been extensively associated with various neurodevelopmental disorders, including developmental delay, intellectual disability, attention-deficit/hyperactivity disorder, epilepsy, schizophrenia, obsessive-compulsive disorder, and encephalopathy [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref015">15</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref017">17</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref018">18</xref>].</p>
<p>In line with the strong involvement of <italic>GRIN2B</italic> in diverse brain disorders, mice carrying a conventional homozygous deletion of <italic>Grin2b</italic> display impaired suckling, neonatal death during postnatal day (P) 1–3, and impaired hippocampal long-term depression (LTD) in neonates [<xref ref-type="bibr" rid="pbio.3000717.ref019">19</xref>]. Similarly, a homozygous truncation of the intracellular C-terminal region of GluN2B causes perinatal lethality in mice [<xref ref-type="bibr" rid="pbio.3000717.ref020">20</xref>]. These early studies were followed by those restricting homozygous <italic>Grin2b</italic> deletion to specific cell types and developmental stages to circumvent the strong developmental impacts of <italic>Grin2b</italic> deletion, which revealed the important roles of GluN2B in the regulation of long-term potentiation (LTP), LTD, and cognitive behaviors [<xref ref-type="bibr" rid="pbio.3000717.ref021">21</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref023">23</xref>]. Notably, an early study investigated mice with heterozygous (not homozygous) <italic>Grin2b</italic> deletion and reported impaired LTP at the mutant hippocampal fimbrial-CA3 synapses [<xref ref-type="bibr" rid="pbio.3000717.ref024">24</xref>], although associated behaviors were not investigated. Conversely, <italic>Grin2b</italic> overexpression has been shown to enhance LTP and learning and memory in mice [<xref ref-type="bibr" rid="pbio.3000717.ref025">25</xref>]. These results suggest that GluN2B is important for normal brain development, synaptic plasticity, and cognitive behaviors.</p>
<p>However, dissimilar to the previous studies on <italic>Grin2b</italic> mice largely analyzing the synaptic and behavioral impacts of a homozygous <italic>Grin2b</italic> deletion, <italic>GRIN2B</italic> mutations identified in human brain disorders are preponderantly heterozygous mutations, and synaptic and behavioral phenotypes of heterozygous <italic>Grin2b</italic>-mutant mice remain largely unexplored. In addition, human <italic>GRIN2B</italic> mutations are often missense mutations that induce a single amino acid change in the encoded protein, again distinct from the null or truncation mutations previously studied in mice. Although many of the missense mutations of NMDAR subunits have been characterized in vitro [<xref ref-type="bibr" rid="pbio.3000717.ref026">26</xref>], their in vivo impacts have been minimally studied.</p>
<p>In the present study, we generated and characterized a knock-in mouse line carrying an ASD-risk mutation (GluN2B-C456Y) in the <italic>Grin2b</italic> gene, a de novo mutation identified in a male individual with ASD and intellectual disability [<xref ref-type="bibr" rid="pbio.3000717.ref012">12</xref>]. These heterozygous GluN2B-C456Y mutant mice (<italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup>) showed substantial decreases in GluN2B protein levels, suggestive of mutation-induced protein degradation in vivo. Currents of GluN2B-containing NMDARs and NMDAR-dependent LTD (but not LTP) were also decreased, revealing sensitivity of LTD to GluN2B haploinsufficiency. Behaviorally, these mice showed normal social interaction but enhanced anxiety-like behavior in pups and contrasting anxiolytic-like behavior in juveniles and adults. These synaptic and behavioral effects were largely mimicked by an independent mouse line carrying a conventional heterozygous <italic>Grin2b</italic> deletion (<italic>Grin2b</italic><sup><italic>+/–</italic></sup>). Importantly, early, but not late, treatment of young mice (P7–16) with the NMDAR agonist D-cycloserine normalized NMDAR currents and LTD in juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice and improved anxiolytic-like behavior in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, supporting the emerging concept in the field of neurodevelopmental and neuropsychiatric disorders that early and timely correction of key pathophysiological deficits is important for efficient and long-lasting beneficial effects.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>Structural and functional impacts of the GluN2B-C456Y mutation on GluN1/GluN2B receptors</title>
<p>Structural analysis has suggested that a missense mutation in the <italic>GRIN2B</italic> gene leading to a C456Y mutation in the GluN2B subunit of NMDARs disrupts a disulfide bond within a loop residing at the interface between the amino-terminal domain (ATD) and ligand-binding domain (LBD) [<xref ref-type="bibr" rid="pbio.3000717.ref027">27</xref>]. In addition, experiments using <italic>Xenopus</italic> oocytes and human embryonic kidney 293 (HEK-293) cells have shown that the GluN2B-C456Y mutation induces multiple changes in the GluN2B protein, including protein degradation, limited surface trafficking, and gating alterations of GluN2B-containing NMDARs [<xref ref-type="bibr" rid="pbio.3000717.ref027">27</xref>].</p>
<p>Our own structural investigation and functional characterization of the GluN2B-C456Y protein using <italic>Xenopus</italic> oocytes yielded overall similar results. Specifically, structural modeling, based on the known structure of GluN1/GluN2B NMDARs [<xref ref-type="bibr" rid="pbio.3000717.ref028">28</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref030">30</xref>], revealed that the GluN2B-C456Y mutation in the LBD region alters the structure of a large loop protruding from the GluN2B LBD by disrupting the formation of an intraloop disulfide bond (<xref ref-type="supplementary-material" rid="pbio.3000717.s001">S1A and S1B Fig</xref>). This loop, which is absent in alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors, makes extensive intra- and intersubunit interactions within neighboring domains pointing to an important role in receptor assembly [<xref ref-type="bibr" rid="pbio.3000717.ref028">28</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref030">30</xref>]. It is therefore likely that the GluN2B-C456Y mutation alters the receptor quaternary structure and in turn its function.</p>
<p>Diheteromers produced by coexpressing GluN2B-C456Y and wild-type (WT) GluN1 yielded NMDAR currents that were &lt;1% of the currents produced by WT GluN1/GluN2B diheteromers (<xref ref-type="supplementary-material" rid="pbio.3000717.s002">S2A Fig</xref>), thus revealing a strong expression phenotype, as previously observed [<xref ref-type="bibr" rid="pbio.3000717.ref027">27</xref>]. Functional characterization of the small-amplitude mutant receptor currents showed an approximately 30% increase in receptor channel maximal open probability, as assessed by MK-801 inhibition kinetics [<xref ref-type="bibr" rid="pbio.3000717.ref031">31</xref>], likely due to a decreased inhibition by ambient protons, as indicated by full proton dose-response curves (<xref ref-type="supplementary-material" rid="pbio.3000717.s002">S2B and S2C Fig</xref>). In agreement with a decreased pH sensitivity, potentiation by spermine, a GluN2B-specific positive allosteric modulator [<xref ref-type="bibr" rid="pbio.3000717.ref032">32</xref>], was also significantly reduced (<xref ref-type="supplementary-material" rid="pbio.3000717.s002">S2D Fig</xref>). In addition, sensitivity to glycine was decreased, whereas sensitivities to glutamate and zinc, an endogenous allosteric inhibitor of NMDARs [<xref ref-type="bibr" rid="pbio.3000717.ref033">33</xref>], were minimally affected (<xref ref-type="supplementary-material" rid="pbio.3000717.s002">S2E–S2G Fig</xref>). Overall, these results indicate that the C456Y mutation in GluN2B drastically reduces expression and alter channel functions of recombinant NMDARs most likely because of GluN2B misfolding and degradation.</p>
</sec>
<sec id="sec004">
<title>The GluN2B-C456Y mutation decreases GluN2B and GluN1 protein levels and GluN2B-containing NMDAR currents in mice</title>
<p>To explore the impacts of the C456Y mutation on the stability or function of GluN2B in mice, we generated a knock-in mouse line carrying the C456Y mutation in the <italic>Grin2b</italic> gene (<xref ref-type="fig" rid="pbio.3000717.g001">Fig 1A</xref>; <xref ref-type="supplementary-material" rid="pbio.3000717.s003">S3A and S3B Fig</xref>). Homozygous C456Y-mutant (<italic>Grin2b</italic>
<sup><italic>C456Y/C456Y</italic></sup>) mice showed neonatal death at P7 (approximately 0% survival), similar to the case for mice with a conventional homozygous <italic>Grin2b</italic> deletion [<xref ref-type="bibr" rid="pbio.3000717.ref019">19</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref020">20</xref>]. In contrast, our heterozygous mutant (<italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup>) mice were produced with the expected mendelian ratios and showed normal survival and growth.</p>
<fig id="pbio.3000717.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.3000717.g001</object-id>
<label>Fig 1</label>
<caption>
<title>The GluN2B-C456Y mutation leads to decreases in GluN2B and GluN1 protein levels and GluN2B-containing NMDAR currents in mice.</title>
<p>(A) Verification of the GluN2B-C456Y mutation in HT and homozygous (“Homo”) KI mice, and validation of its absence in WT mice, by DNA sequencing. (B) Decreased levels of GluN2B protein in the <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> brain. Whole-brain fractions from <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice at multiple developmental stages (E20, P14, P21, P28, and P56) were immunoblotted with anti-GluN1/2A/2B antibodies. Note that levels of GluN1 protein are also decreased, although to a lesser extent than those of GluN2B. For purposes of quantification, average levels of GluN1, Glu2A, and Glu2B proteins from <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice were normalized to those from WT mice. <italic>n</italic> = 4 mice for WT and HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, Student <italic>t</italic> test. (C) Decreased ratio of evoked NMDAR- and AMPAR-mediated EPSCs (NMDA/AMPA ratio) at hippocampal SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P19–23). Note the faster decay kinetics of the mutant NMDAR currents, indicative of a decrease in the GluN2B component. <italic>n</italic> = 10 neurons from 5 mice for WT, and 9 (5) for HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, Student <italic>t</italic> test. (D) Decreased proportion of ifenprodil-sensitive currents of GluN2B-containing NMDARs at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P21–23). <italic>n</italic> = 10 neurons (7 mice) for WT and HT, **<italic>P</italic> &lt; 0.01, Student <italic>t</italic> test. (E) Normal levels of basal excitatory synaptic transmission at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P27–41), as shown by the input-output relationship of evoked EPSCs. <italic>n</italic> = 10 slices from 3 mice for WT and HT, one-way ANOVA. (F) Normal levels of paired-pulse facilitation at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P27–41). <italic>n</italic> = 10 slices (3 mice) for WT and HT, one-way ANOVA. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. AMPA, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AMPAR, AMPA receptor; E, embryonic day; EPSC, excitatory postsynaptic current; fEPSP, field excitatory postsynaptic potential; HT, heterozygous; KI, knock-in; NMDA, N-methyl-D-aspartate; NMDAR, NMDA receptor; ns, not significant; P, postnatal day; SC-CA1, Schaffer collateral-CA1 pyramidal; WT, wild type.</p>
</caption>
<graphic xlink:href="pbio.3000717.g001"></graphic>
</fig>
<p>Immunoblot analyses of whole-brain lysates and crude synaptosomal fractions from <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice at embryonic day 20 (E20) and several postnatal stages (P14, P21, P28, and P56) indicated approximately 30%–50% reductions in the levels of GluN2B protein (<xref ref-type="fig" rid="pbio.3000717.g001">Fig 1B</xref>; <xref ref-type="supplementary-material" rid="pbio.3000717.s004">S4A Fig</xref>). Notably, the levels of GluN1, but not GluN2A, were also reduced, although to a lesser extent than those of GluN2B, indicating that the stability of GluN1 strongly depends on GluN2B, whereas that of GluN2A does not. However, the C456Y mutation had no effect on mRNA levels of <italic>Grin2b</italic> or <italic>Grin1</italic> (encoding GluN1) (<xref ref-type="supplementary-material" rid="pbio.3000717.s004">S4B Fig</xref>). These results indicate that the GluN2B-C456Y mutation induces a strong reduction in the levels of the GluN2B protein as well as a concomitant reduction in GluN1 protein levels in vivo, without affecting their mRNA levels.</p>
<p>We next tested whether the GluN2B-C456Y mutation affects NMDAR currents in the hippocampus of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. This mutation caused significant decreases in the ratio of NMDAR/AMPA receptor (AMPAR)-mediated evoked excitatory postsynaptic currents (EPSCs), tau of NMDAR current decay, and the amount of ifenprodil-sensitive current of GluN2B-containing NMDARs at Schaffer collateral-CA1 pyramidal (SC-CA1) synapses (<xref ref-type="fig" rid="pbio.3000717.g001">Fig 1C and 1D</xref>). In contrast, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> SC-CA1 synapses showed a normal input-output relationship of evoked EPSCs and paired-pulse facilitation (<xref ref-type="fig" rid="pbio.3000717.g001">Fig 1E and 1F</xref>), indicative of normal AMPAR-mediated basal excitatory synaptic transmission and presynaptic release. These results suggest that the GluN2B-C456Y mutation selectively suppresses currents of GluN2B-containing NMDARs at hippocampal SC-CA1 synapses.</p>
</sec>
<sec id="sec005">
<title>The GluN2B-C456Y mutation reduces hippocampal NMDAR-dependent LTD without affecting LTP or mGluR-LTD</title>
<p>Previous studies on <italic>Grin2b</italic>-mutant mice have demonstrated the critical roles of GluN2B in the regulation of synaptic plasticity such as LTP and LTD [<xref ref-type="bibr" rid="pbio.3000717.ref019">19</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref024">24</xref>], although the majority of these studies used mice carrying homozygous <italic>Grin2b</italic> deletion.</p>
<p>However, these observations are not congruent with human cases of <italic>GRIN2B</italic> mutations and related brain dysfunctions, in which heterozygous <italic>GRIN2B</italic> mutations are prevalent [<xref ref-type="bibr" rid="pbio.3000717.ref001">1</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref011">11</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref017">17</xref>]. Thus, whether <italic>Grin2b</italic> haploinsufficiency in <italic>Grin2b</italic>-mutant mice would affect various forms of hippocampal synaptic plasticity or other synaptic functions is an important question that needs to be addressed. This question becomes more complicated when we consider the juvenile and adult stages, when both GluN2B and GluN2A are expressed and contribute to the formation of multiple forms of NMDARs with different subunit compositions, including diheteromeric (1/2A or 1/2B) and triheteromeric (1/2A/2B) NMDAR complexes [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref034">34</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref035">35</xref>].</p>
<p>To address this question, we measured several forms of synaptic plasticity in addition to low-frequency stimulation (LFS)-LTD, including LTP induced by high-frequency stimulation (HFS-LTP), theta burst stimulation–induced LTP (TBS-LTP), and metabotropic glutamate receptor (mGluR)-dependent LTD (mGluR-LTD) in the CA1 region of the <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampus at juvenile stages (P16–33).</p>
<p>The GluN2B-C456Y mutation reduced LFS-LTD by about 55% at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> SC-CA1 synapses compared with WT mice (<xref ref-type="fig" rid="pbio.3000717.g002">Fig 2A</xref>), a result similar to that obtained in neonatal mice with a conventional homozygous <italic>Grin2b</italic> deletion [<xref ref-type="bibr" rid="pbio.3000717.ref019">19</xref>]. A similar decrease (approximately 84%) in LFS-LTD was observed in the prelimbic layer 1 region of the medial prefrontal cortex (mPFC) (<xref ref-type="fig" rid="pbio.3000717.g002">Fig 2B</xref>). This result provides genetic evidence that LFS-LTD in the hippocampus is sensitive to <italic>Grin2b</italic> haploinsufficiency.</p>
<fig id="pbio.3000717.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.3000717.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Reduced LFS-LTD but normal mGluR-LTD, HFS-LTP, TBS-LTP, and PSD density and morphology in the <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampus.</title>
<p>(A) Reduced LFS-LTD at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P17–19). <italic>n</italic> = 9 neurons from 7 mice for WT (75.9% ± 2.4%), and 9 (5) for HT (89.1% ± 2.1%), ***<italic>P</italic> &lt; 0.001, Student <italic>t</italic> test. (B) Reduced LFS-LTD in the PrL 1 region of the mPFC in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P17–20). <italic>n</italic> = 9 neurons from 5 mice for WT (82.9% ± 2.8%), and 10 (5) for HT (97.3% ± 5.8%), *<italic>P</italic> &lt; 0.05, Student <italic>t</italic> test. (C) Normal mGluR-LTD induced by the group I mGluR agonist DHPG (50 μM for 10 minutes) at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P16–20). <italic>n</italic> = 8 (6) for WT (59.3% ± 5.8%), and 8 (4) for HT (67.6% ± 6.4%), Student <italic>t</italic> test. (D) Normal HFS-LTP at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P27–33). <italic>n</italic> = 9 (5) for WT (132.5% ± 6.8%), and 10 (4) for HT (130.0% ± 3.2%), Mann-Whitney test. (E) Normal TBS-LTP at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P28–32). <italic>n</italic> = 11 (6) for WT (159.4% ± 6.6%), and 9 (4) for HT (148.5% ± 4.9%), Student <italic>t</italic> test. (F) Normal PSD density and morphology (length, depth, and perforation) in the CA1 region of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P21). <italic>n</italic> = 3 mice for WT and HT, Student <italic>t</italic> test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. DHPG, dihydroxyphenylglycine; fEPSP, field excitatory postsynaptic potential; HFS, high-frequency stimulation; HT, heterozygous; LTD, long-term depression; LFS, low-frequency stimulation; LTP, long-term potentiation; mGluR, metabotropic glutamate receptor; mPFC, medial prefrontal cortex; ns, not significant; P, postnatal day; PrL, prelimbic layer; PSD, postsynaptic density; SC-CA1, Schaffer collateral-CA1 pyramidal; TBS, theta burst stimulation; WT, wild type.</p>
</caption>
<graphic xlink:href="pbio.3000717.g002"></graphic>
</fig>
<p>In contrast, the GluN2B-C456Y mutation had no effect on mGluR-LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG) at SC-CA1 synapses of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (<xref ref-type="fig" rid="pbio.3000717.g002">Fig 2C</xref>). It also had no effect on HFS-LTP or TBS-LTP at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> SC-CA1 synapses (<xref ref-type="fig" rid="pbio.3000717.g002">Fig 2D and 2E</xref>). These results suggest that the heterozygous C456Y mutation and consequent decreases in GluN2B protein levels, GluN2B-dependent NMDAR currents, and LFS-LTD have no effect on other forms of synaptic plasticity in the hippocampus.</p>
<p>Because LTD is implicated in the regulation of synapse shrinkage and pruning [<xref ref-type="bibr" rid="pbio.3000717.ref036">36</xref>], we attempted an electron microscopic (EM) analysis to see whether <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice display altered density or morphology of excitatory synapses. However, there were no genotype differences in the density and morphology (length, depth, and perforation [a measure of maturation]) of postsynaptic density (PSD) structures in the CA1 region of the WT and <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampus (P21) (<xref ref-type="fig" rid="pbio.3000717.g002">Fig 2F</xref>), electron-dense multiprotein complexes at excitatory postsynaptic sites [<xref ref-type="bibr" rid="pbio.3000717.ref037">37</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref038">38</xref>], suggesting that a moderate (approximately 50%) decrease in LTD does not induce morphological changes of excitatory synapses.</p>
</sec>
<sec id="sec006">
<title>The GluN2B-C456Y mutation does not affect spontaneous excitatory or inhibitory synaptic transmission or neuronal excitability</title>
<p>A previous study employed single-neuron gene deletion to show that GluN2A and GluN2B distinctly regulate the number and strength of functional excitatory synapses [<xref ref-type="bibr" rid="pbio.3000717.ref039">39</xref>]. In addition, GluN2B is expressed in GABAergic interneurons [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>] and NMDARs can function at presynaptic sites [<xref ref-type="bibr" rid="pbio.3000717.ref040">40</xref>]. It is therefore possible that a heterozygous GluN2B-C456Y mutation might influence synaptic features unrelated to synaptic plasticity, such as synapse development and spontaneous synaptic transmission, at both excitatory and inhibitory synapses. In addition, mutations expected to mainly affect excitatory synapses are frequently associated with changes in intrinsic neuronal properties, such as neuronal excitability [<xref ref-type="bibr" rid="pbio.3000717.ref041">41</xref>], suggesting that the GluN2B-C456Y mutation might also affect neuronal properties. To test these possibilities, we first measured spontaneous synaptic transmission at excitatory and inhibitory <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> synapses.</p>
<p>The frequency and amplitude of miniature EPSCs (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) did not differ in CA1 pyramidal neurons in the hippocampus of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice compared with those of WT animals (<xref ref-type="supplementary-material" rid="pbio.3000717.s005">S5A and S5B Fig</xref>), suggestive of normal development and efficacy of excitatory and inhibitory synapses. Moreover, there were no differences between genotypes in spontaneous EPSCs (sEPSCs) or spontaneous IPSCs (sIPSCs), measured in the absence of tetrodotoxin to allow network activities (<xref ref-type="supplementary-material" rid="pbio.3000717.s005">S5C and S5D Fig</xref>), suggesting that excitatory network activity is unaltered in the hippocampus of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. We also measured the ratio of evoked EPSCs and IPSCs in the CA1 hippocampal region and found no genotype difference (<xref ref-type="supplementary-material" rid="pbio.3000717.s005">S5E Fig</xref>).</p>
<p>In addition to spontaneous and evoked synaptic transmission, neural excitability was unaltered in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> CA1 pyramidal neurons, as shown by current-firing curves (<xref ref-type="supplementary-material" rid="pbio.3000717.s005">S5F Fig</xref>). These results collectively suggest that, in contrast to its effects on LFS-LTD, the heterozygous GluN2B-C456Y mutation does not affect neuronal excitability or excitatory or inhibitory synapse development or function in the hippocampus in the presence or absence of network activity.</p>
</sec>
<sec id="sec007">
<title><italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice display hypoactivity, anxiolytic-like behavior, and moderate repetitive self-grooming</title>
<p>To explore behavioral impacts of the GluN2B-C456Y mutation, we subjected <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice to a battery of behavioral tests. Adult male <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice displayed hypoactivity in the open-field test (<xref ref-type="fig" rid="pbio.3000717.g003">Fig 3A and 3B</xref>) but spent normal amounts of time in the center region of the open-field arena, indicative of largely normal anxiety-like behavior (<xref ref-type="fig" rid="pbio.3000717.g003">Fig 3C and 3D</xref>). These mice, however, displayed anxiolytic-like behavior during the first 10 minutes in the arena, likely reflecting a modified response to a novel environment.</p>
<fig id="pbio.3000717.g003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.3000717.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Adult and juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice display hypoactivity and anxiolytic-like behavior, whereas <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups show anxiety-like enhanced USVs upon mother separation.</title>
<p>(A–D) Hypoactivity, but normal anxiety-like behavior, in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P68–78) in the open-field test, as shown by distance moved and time spent in the center region of the open-field arena. <italic>n</italic> = 28 mice for WT and HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Sidak’s test and Mann-Whitney test. (E–H) Anxiolytic-like behavior in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P70–124) in the elevated plus-maze, as shown by entries into and time spent in closed/open arms. <italic>n</italic> = 12 mice for WT and HT, *<italic>P</italic> &lt; 0.05, Student <italic>t</italic> test (time in closed arms and closed-arm entry number) and Mann-Whitney test (time in open arms and open-arm entry number). (I) Normal anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P75) in the light-dark test, as shown by time spent in the light chamber. <italic>n</italic> = 15 mice for WT and 16 for HT, Mann-Whitney test. (J–L) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups (P4–12) emit strongly increased USVs upon mother separation, as shown by the total number of USV calls, duration of each USV calls, and latency to first calls. <italic>n</italic> = 62 (WT) and 38 (HT), *<italic>P</italic> &lt; 0.05, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Sidak’s test. (M–P) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles (P19–21) show modest hypoactivity and anxiolytic-like behavior in the open-field test, as shown by distance moved and time spent in the center region of the open-field arena. <italic>n</italic> = 24 mice for WT and 20 for HT, **<italic>P</italic> &lt; 0.01, two-way ANOVA with Sidak’s test, Student <italic>t</italic> test (distance moved) and Mann-Whitney test (center time). The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. HT, heterozygous; ns, not significant; P, postnatal day; USV, ultrasonic vocalization; WT, wild type.</p>
</caption>
<graphic xlink:href="pbio.3000717.g003"></graphic>
</fig>
<p>In the elevated plus-maze, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice also showed anxiolytic-like behavior, as shown by both the number of entries into and time spent in closed/open arms (<xref ref-type="fig" rid="pbio.3000717.g003">Fig 3E–3H</xref>). In contrast, these mice showed normal anxiety-like behaviors in the light-dark test, as shown by time spent in the light chamber (<xref ref-type="fig" rid="pbio.3000717.g003">Fig 3I</xref>). These results suggest that <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice display anxiolytic-like behavior in the elevated plus-maze.</p>
<p>In tests measuring learning and memory, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice showed normal levels of learning and memory in the learning and probe phases of both initial- and reversal-learning sessions of the Morris water maze (<xref ref-type="supplementary-material" rid="pbio.3000717.s006">S6A–S6E Fig</xref>). In addition, they showed a normal preference for a novel object over a familiar object in the novel object–recognition test (<xref ref-type="supplementary-material" rid="pbio.3000717.s006">S6F Fig</xref>).</p>
<p>Contrary to our expectation, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice showed largely normal social behaviors, including social approach and social novelty recognition in the three-chamber test [<xref ref-type="bibr" rid="pbio.3000717.ref042">42</xref>]; social interaction between freely moving mice in the direct social-interaction test; and ultrasonic vocalizations (USVs), a form of social communication in rodents, upon encountering a female (<xref ref-type="supplementary-material" rid="pbio.3000717.s007">S7A–S7N Fig</xref>) [<xref ref-type="bibr" rid="pbio.3000717.ref042">42</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref044">44</xref>].</p>
<p>Furthermore, these mice showed enhanced self-grooming (but normal digging) in home cages with bedding but showed no repetitive self-grooming in a novel chamber without bedding (<xref ref-type="supplementary-material" rid="pbio.3000717.s007">S7O–S7Q Fig</xref>), indicative of a moderate increase in self-grooming. These results collectively suggest that the GluN2B-C456Y mutation leads to hypoactivity, anxiolytic-like behavior, and moderately enhanced self-grooming, without affecting social interaction, social communication, or learning and memory in mice.</p>
</sec>
<sec id="sec008">
<title>A conventional heterozygous <italic>Grin2b</italic> deletion in mice leads to hypoactivity and anxiolytic-like behavior</title>
<p>We next employed an independent mouse line carrying a conventional heterozygous <italic>Grin2b</italic> deletion (<italic>Grin2b</italic><sup><italic>+/–</italic></sup>) to see whether the behavioral phenotypes observed in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice could be reproduced. This mouse line has been used previously to demonstrate that a homozygous null <italic>Grin2b</italic> mutation entirely eliminates GluN2B protein and causes severe phenotypes, including impaired suckling and neonatal death [<xref ref-type="bibr" rid="pbio.3000717.ref019">19</xref>].</p>
<p><italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice showed decreased (approximately 50%) whole-brain levels of the GluN2B, but not GluN1 or GluN2A, subunit of NMDARs at P14 and P21 (<xref ref-type="supplementary-material" rid="pbio.3000717.s008">S8A and S8B Fig</xref>), partly similar to the results from <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice in which both GluN2B and GluN1 levels were decreased (P14 and P21). Behaviorally, adult male <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice showed phenotypes that were largely similar to those observed in adult male <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, including hypoactivity and moderately anxiolytic-like behavior (<xref ref-type="supplementary-material" rid="pbio.3000717.s008">S8C–S8K Fig</xref>), as well as normal social interaction and communication and object-recognition memory (<xref ref-type="supplementary-material" rid="pbio.3000717.s009">S9A–S9K</xref> and <xref ref-type="supplementary-material" rid="pbio.3000717.s009">S9N Fig</xref>). Unlike <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, which showed modestly enhanced self-grooming, <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice showed no repetitive self-grooming (<xref ref-type="supplementary-material" rid="pbio.3000717.s009">S9L and S9M Fig</xref>).</p>
<p>These results indicate that the heterozygous C456Y mutation and conventional <italic>Grin2b</italic> heterozygosis lead to similar, although not identical, biochemical and behavioral phenotypes and suggest that the phenotypes observed in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice are likely consequences of the loss (not gain) of GluN2B function. The small differences in the behaviors of the two mouse lines may reflect minor effects attributable to the specific mutation/deletion in the <italic>Grin2b</italic> gene.</p>
</sec>
<sec id="sec009">
<title><italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups show anxiety-like behavior whereas <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles show normal or anxiolytic-like behavior</title>
<p>ASD is characterized by early onset of core and comorbid symptoms. When <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups (P4–12) were tested for the emission of USVs upon mother separation, a measure of anxiety in rodents responsive to anxiolytic medications [<xref ref-type="bibr" rid="pbio.3000717.ref045">45</xref>], these pups showed strongly enhanced USVs, as determined by the total number of USV calls, duration of each USV calls, and latency to first calls (<xref ref-type="fig" rid="pbio.3000717.g003">Fig 3J–3L</xref>). This suggests that <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups display anxiety-like behaviors, similar to the anxiety symptoms comorbid with human ASD [<xref ref-type="bibr" rid="pbio.3000717.ref046">46</xref>].</p>
<p>When <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles (P18–26) were subjected to a battery of behavioral tests, they displayed hypoactivity, similar to adult mice, and, notably, strong anxiolytic-like behavior in the center region of the open-field arena (<xref ref-type="fig" rid="pbio.3000717.g003">Fig 3M–3P</xref>). However, upon mother separation and reunification in a mother-homing test, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles spent normal amounts of time with the reunited mothers (<xref ref-type="supplementary-material" rid="pbio.3000717.s010">S10A and S10B Fig</xref>), suggestive of normal anxiety-like behaviors. Therefore, anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups seems to be strongly weakened or changed into anxiolytic-like behavior at juvenile stages, similar to the anxiolytic-like behaviors in adults.</p>
<p><italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles showed normal social interaction, as shown by the juvenile play test (<xref ref-type="supplementary-material" rid="pbio.3000717.s010">S10C Fig</xref>), similar to adult mice. In addition, these mice showed normal self-grooming and digging in home cages with bedding (<xref ref-type="supplementary-material" rid="pbio.3000717.s010">S10D and S10E Fig</xref>), partly dissimilar to the adult mutant mice that show enhanced self-grooming but normal digging in home cages with bedding. These results suggest that self-grooming in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice develops slowly in late life after the juvenile stage.</p>
</sec>
<sec id="sec010">
<title>Early correction of NMDAR function and NMDAR-dependent LTD by D-cycloserine improves anxiolytic-like behavior in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice</title>
<p>The reduced NMDAR function and LTD observed in young (2–3-week-old) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice might be associated with the behavioral abnormalities (hypoactivity and anxiolytic-like behavior) observed in adult (2–4-month-old) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. This hypothesis could be tested by normalizing the reduced NMDAR function and NMDAR-dependent LTD in early stages and examining whether these corrections are associated with behavioral rescues at late stages. To this end, we used D-cycloserine, a partial agonist at the glycine-binding site of NMDARs with increasing potential for the treatment of neurological and neuropsychiatric disorders [<xref ref-type="bibr" rid="pbio.3000717.ref047">47</xref>].</p>
<p>We first tested whether the reduced LFS-LTD is attributable to decreased NMDAR currents in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. In hippocampal slices from young <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, application of D-cycloserine (10 μM), which can still activate mutant GluN2B-C456Y receptors (<xref ref-type="supplementary-material" rid="pbio.3000717.s002">S2H Fig</xref>), fully normalized the reduced LFS-LTD at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> SC-CA1 synapses, without affecting WT synapses (<xref ref-type="fig" rid="pbio.3000717.g004">Fig 4A</xref>). These results suggest that abnormal NMDAR currents are associated with reduced LFS-LTD at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampal SC-CA1 synapses in juvenile mice.</p>
<fig id="pbio.3000717.g004" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.3000717.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Early correction of NMDAR function and NMDAR-dependent LTD by DCS treatment improves anxiolytic-like behavior, but not hypoactivity, in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A) Acute treatment with 10 μM DCS normalizes LFS-LTD at SC-CA1 synapses in hippocampal slices from juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P17–19) without affecting WT synapses. <italic>n</italic> = 11 cells (4 mice) for WT_V (69.0% ± 7.7%), 12 (4) for WT_D (72.4% ± 2.4%), 9 (4) for HT_V (90.2% ± 2.4%), 10 (4) for HT_D (73.9% ± 3.1%), ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Tukey’s test. (B) Experimental strategy for chronic, oral DCS treatment (40 mg/kg), twice daily for 10 days (P7–16), in young <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice followed by measurements of NMDA/AMPA ratio, paired-pulse facilitation, and LTD in juvenile mice (P17–21) and behavioral tests (EPM and OFT) in adult mice (&gt;P56). (C) Early chronic oral DCS treatment (40 mg/kg) normalizes the decreased NMDA/AMPA ratio at SC-CA1 synapses in juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P19–23). <italic>n</italic> = 9 cells from 4 mice for WT_V, 11 (5) for WT_D, 11 (5) for HT_V, 11 (3) for HT_D, *<italic>P</italic> &lt; 0.05, two-way ANOVA with Tukey’s test. (D) Early chronic oral DCS treatment (40 mg/kg) normalizes LFS-LTD at SC-CA1 synapses in juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P17–20). <italic>n</italic> = 14 slices from 5 mice for WT_V (79.5% ± 2.0%), 13 (6) for WT_D (77.2% ± 3.2%), 13 (8) for HT_V (92.0% ± 3.2%), 15 (7) for HT_D (78.1% ± 2.6%), *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, two-way ANOVA with Tukey’s test. (E) Early chronic oral DCS treatment (40 mg/kg) does not affect paired-pulse facilitation at SC-CA1 synapses in juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P26–28). <italic>n</italic> = 12 (3) for WT_V, 12 (3) for WT_D, 11 (3) for HT_V, 12 (3) for HT_D, two-way ANOVA with Tukey’s test. (F–I) Early chronic oral DCS treatment (40 mg/kg) improves anxiolytic-like behavior in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P63–73). <italic>n</italic> = 19 mice for WT_D, 18 for WT_D, 17 for HT_V, 16 for HT_D, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, two-way ANOVA with Tukey’s test. (J–M) Early chronic oral DCS treatment (40 mg/kg) has no effect on hypoactivity in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P60–71). Note that early DCS treatment did not affect the time spent in the center by WT or mutant mice. <italic>n</italic> = 25 mice for WT_D, 24 for WT_D, 26 for HT_V, 26 for HT_D, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Tukey’s test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. AMPA, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; DCS, D-cycloserine; EPM, elevated plus-maze; fEPSP, field excitatory postsynaptic potential; HT, heterozygous; HT_D, HT with DCS; HT_V, HT with vehicle; LFS, low-frequency stimulation; LTD, long-term depression; NMDA, N-methyl-D-aspartate; NMDAR, NMDA receptor; ns, not significant; OFT, open-field test; P, postnatal day; SC-CA1, Schaffer collateral-CA1 pyramidal; WT, wild type; WT_D, WT with DCS; WT_V, WT with vehicle.</p>
</caption>
<graphic xlink:href="pbio.3000717.g004"></graphic>
</fig>
<p>We next attempted early, chronic treatment of young <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice with D-cycloserine (40 mg/kg), administered orally twice daily for 10 days (P7–16), followed by measurements of NMDA/AMPA ratio, paired-pulse facilitation, and LFS-LTD in juvenile mice (P17–21) and behavioral experiments in adult mice (&gt;P56) (<xref ref-type="fig" rid="pbio.3000717.g004">Fig 4B</xref>). Early D-cycloserine treatment fully normalized the reduced NMDA/AMPA ratio and LFS-LTD at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> SC-CA1 synapses in juvenile mice (P16–21), without affecting paired-pulse facilitation (<xref ref-type="fig" rid="pbio.3000717.g004">Fig 4C–4E</xref>). WT synapses were unaffected in these measurements.</p>
<p>In addition, early D-cycloserine treatment improved anxiolytic-like behavior in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice in the elevated plus-maze test, without affecting WT mice (<xref ref-type="fig" rid="pbio.3000717.g004">Fig 4F–4I</xref>). In contrast, D-cycloserine had no effect on hypoactivity in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (<xref ref-type="fig" rid="pbio.3000717.g004">Fig 4J–4M</xref>). We could not test whether early D-cycloserine treatment (P7–16) could affect pup USVs in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice because the time window for the treatment fell after the early time window for pup USV (P4–12).</p>
<p>When <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice carrying conventional heterozygous <italic>Grin2b</italic> deletion were tested for D-cycloserine-dependent rescue of synaptic and behavioral deficits, early chronic D-cycloserine treatment (P7–16, 40 mg/kg, twice daily for 10 days; oral) normalized the decreased LFS-LTD at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> SC-CA1 synapses, without affecting WT synapses (<xref ref-type="supplementary-material" rid="pbio.3000717.s011">S11A and S11B Fig</xref>). Early D-cycloserine treatment also had no effect on the hypoactivity of <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (<xref ref-type="supplementary-material" rid="pbio.3000717.s011">S11C Fig</xref>), similar to the results from <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. We could not determine whether D-cycloserine has any effect on the anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (<xref ref-type="supplementary-material" rid="pbio.3000717.s011">S11C Fig</xref>) because the anxiolytic-like behavior in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice was weaker than that in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, and the small baseline difference between WT and <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice became insignificant (between vehicle-treated WT and <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice) by the chronic drug treatment procedures (oral, twice/day for 10 days).</p>
</sec>
<sec id="sec011">
<title>Late NMDAR activation by D-cycloserine does not improve anxiolytic-like behavior or hypoactivity in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice</title>
<p><italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice display decreased GluN2B levels at an adult stage (P56), suggesting that the continuing decrease in GluN2B levels in adult mutant mice, in addition to the reduced LFS-LTD in young mutant mice, might be associated with anxiety-like behavior or hypoactivity. To test this, we attempted to enhance NMDAR function in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice by treating with D-cycloserine. In these experiments, we first used an acute treatment paradigm because acute D-cycloserine treatment has been previously shown to rescue ASD-like behaviors in many mouse models of ASD [<xref ref-type="bibr" rid="pbio.3000717.ref009">9</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref010">10</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref048">48</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref050">50</xref>].</p>
<p>In contrast to early chronic treatment, late acute D-cycloserine treatment (20 mg/kg; intraperitoneal [i.p.]) in the adult stage had no effect on anxiolytic-like behavior or hypoactivity in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice in open-field or elevated plus-maze tests (<xref ref-type="fig" rid="pbio.3000717.g005">Fig 5A–5I</xref>); it also had no effect on WT mice. In addition, late chronic D-cycloserine treatment (P57–66, 40 mg/kg, twice/day, oral) had no effect on the anxiolytic-like behavior or hypoactivity in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (<xref ref-type="supplementary-material" rid="pbio.3000717.s012">S12 Fig</xref>). However, the late chronic drug treatment procedures using a restrainer substantially blunted the baseline differences in elevated plus-maze variables (but not locomotion) between vehicle-treated WT and mutant mice, making it difficult to assess the drug effects on these values. These results collectively suggest that late treatment of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice with D-cycloserine to enhance NMDAR function has no effect on anxiolytic-like behavior or hypoactivity, highlighting the importance of early treatments.</p>
<fig id="pbio.3000717.g005" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.3000717.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Late acute DCS treatment has no effect on anxiolytic-like behavior or hypoactivity in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A–E) Acute DCS treatment (20 mg/kg; single i.p. injection 30 minutes prior to the experiment) in adult mice (P62–76) does not affect anxiolytic-like behavior in the EPM. <italic>n</italic> = 18 mice for WT_D, 18 for WT_D, 15 for HT_V, 15 for HT_D, **<italic>P</italic> &lt; 0.01, two-way ANOVA with Tukey’s test. (F–I) Acute DCS treatment (20 mg/kg; single i.p. injection 30 minutes prior to the experiment) in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P59–73) does not affect hypoactivity in the OFT. <italic>n</italic> = 21 mice for WT_D, 22 for WT_D, 22 for HT_V, 22 for HT_D, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Tukey’s test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. DCS, D-cycloserine; EPM, elevated plus-maze; HT, heterozygous; HT_D, HT with DCS; HT_V, HT with vehicle; i.p., intraperitoneal; ns, not significant; OFT, open-field test; P, postnatal day; WT, wild type; WT_D, WT with DCS; WT_V, WT with vehicle.</p>
</caption>
<graphic xlink:href="pbio.3000717.g005"></graphic>
</fig>
</sec>
</sec>
<sec id="sec012" sec-type="conclusions">
<title>Discussion</title>
<p>In this study, we demonstrated that mice carrying a heterozygous C456Y mutation in the GluN2B subunit of NMDARs, an ASD-risk mutation in humans, exhibit decreased GluN2B and GluN1 protein levels, diminished currents of GluN2B-containing NMDARs, and reduced LFS-LTD. This mutation also induced anxiolytic-like behavior that can be corrected by early, but not late, D-cycloserine treatment that restores NMDAR function and NMDAR-dependent LTD.</p>
<sec id="sec013">
<title>C456Y mutation and GluN2B proteins</title>
<p>A key finding in our study is that the GluN2B-C456Y mutation induces substantial degradation of the GluN2B protein in mice. This conclusion is supported by the measurement of GluN2B protein levels in the <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> brain at various developmental stages. A previous study on multiple GluN2A/B mutations using structural analysis and oocyte/HEK cell experiments reported similar findings on the impact of the GluN2B-C456Y mutation [<xref ref-type="bibr" rid="pbio.3000717.ref027">27</xref>]. Interestingly, a similar expression phenotype was observed for the patient-derived GluN2A-C436R mutation, which also disrupts a disulfide bond within LBD loop 1 [<xref ref-type="bibr" rid="pbio.3000717.ref031">31</xref>]. Our study extends these previous findings by providing in vivo evidence of the importance of the C456Y mutation and the proper folding of LBD loop 1 for GluN2B protein levels.</p>
<p>Our results further reveal an impact of reduced GluN2B protein levels on GluN1 protein levels, although the magnitude of this latter decrease was less than that of GluN2B. This further supports the previously reported importance of GluN2B in the maintenance of normal levels of GluN1 [<xref ref-type="bibr" rid="pbio.3000717.ref021">21</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref023">23</xref>]. This decrease in the GluN1 subunit in our study does not seem to involve changes in <italic>Grin1</italic> mRNA levels. It may occur because the reduction in GluN2B protein levels may lead to a situation in which some GluN1 proteins that can no longer associate with GluN2B to form heteromeric NMDAR complexes become destabilized and degraded. It is possible that some GluN1 proteins may fail to associate with mutant GluN2B proteins beginning in the endoplasmic reticulum [<xref ref-type="bibr" rid="pbio.3000717.ref007">7</xref>] and are degraded via the ubiquitin-proteasomal pathway following retrograde transport to the cytoplasm [<xref ref-type="bibr" rid="pbio.3000717.ref051">51</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref054">54</xref>]. Alternatively, the two proteins may initially associate with each other and reach the plasma membrane surface and synaptic sites but gradually dissociate from one another, leaving GluN1 subject to endocytosis and degradation through the late endosomal-lysosomal pathway involving a conserved membrane-proximal signal present in GluN1 [<xref ref-type="bibr" rid="pbio.3000717.ref055">55</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref056">56</xref>].</p>
<p>Complicating the situation is the fact that GluN2B can form a triheteromeric complex with GluN1 and GluN2A [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref034">34</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref035">35</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref057">57</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref058">58</xref>] that is known to be the major NMDAR population in the adult hippocampus [<xref ref-type="bibr" rid="pbio.3000717.ref039">39</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref059">59</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref060">60</xref>]. Although further details remain to be elucidated, the concomitant reduction in GluN1 levels creates a situation in which GluN1 protein is produced normally but not used.</p>
<p>In addition, given that diheteromic and triheteromeric NMDAR complexes display distinct biophysical and pharmacological properties in different spatiotemporal contexts [<xref ref-type="bibr" rid="pbio.3000717.ref035">35</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref061">61</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref063">63</xref>], the reduced levels of GluN2B and GluN1 in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice would affect both diheteromic and triheteromeric NMDAR complexes differentially in different brain regions, cell types, and developmental stages.</p>
</sec>
<sec id="sec014">
<title>GluN2B-C456Y and LTD</title>
<p>Another key finding of our study is the reduced NMDAR-dependent LFS-LTD by about 50% at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampal SC-CA1 synapses. Previous studies on genetic <italic>Grin2b</italic> deletion and its impacts on LTD found near-complete impairments of LTD in neonate mice (P1–3) carrying a conventional homozygous <italic>Grin2b</italic> deletion [<xref ref-type="bibr" rid="pbio.3000717.ref019">19</xref>] and in adult mice (14–22 weeks) carrying conditional homozygous <italic>Grin2b</italic> deletion restricted to Ca<sup>2+</sup>/calmodulin dependent protein kinase II (CaMKII)-positive principal neurons in the cortex and hippocampal CA1 region [<xref ref-type="bibr" rid="pbio.3000717.ref021">21</xref>]. The design of our <italic>Grin2b</italic>-mutant mouse study differs from those of the previous studies in the following respects: (1) use of a patient-derived knock-in mutation rather than a conventional, or conditional, gene deletion; (2) use of heterozygous instead of homozygous mutant mice (an early study on heterozygous <italic>Grin2b</italic> mice examined only LTP but not LTD [<xref ref-type="bibr" rid="pbio.3000717.ref024">24</xref>]); and (3) analysis of LTD at a juvenile stage rather than at a neonatal or adult stage. In addition, our results indicate that the heterozygous GluN2B-C456Y mutation has no effect on other synaptic and neuronal variables, such as spontaneous synaptic transmission in CA1 neurons (mEPSCs, mIPSCs, sEPSCs, sIPSCs), basal transmission at SC-CA1 synapses (evoked EPSCs), the ratio of evoked IPSCs and EPSCs, and intrinsic neuronal excitability of CA1 neurons. Moreover, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampal SC-CA1 synapses displayed normal HFS-LTP, TBS-LTP, or mGluR-LTD. The lack of changes in LTP (HFS and TBS) measured during a late juvenile stage (P27–33) could be because the postnatal switch from GluN2B to GluN2A by neuronal activity may be largely complete at this stage [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>]. Together, these results support the established notion that genetic deletion of <italic>Grin2b</italic> suppresses LTD and extends it by demonstrating that the patient-derived heterozygous GluN2B-C456Y mutation induces a selective reduction in LTD by approximately 50% in juvenile mice.</p>
<p>A straightforward mechanism underlying the decreased LFS-LTD at <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampal SC-CA1 synapses would be decreased GluN2B function. Previous studies employing pharmacological inhibitors of GluN2B, however, yielded conflicting results, with their significant effects on LTD [<xref ref-type="bibr" rid="pbio.3000717.ref064">64</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref067">67</xref>] or insignificant effects on LTD [<xref ref-type="bibr" rid="pbio.3000717.ref068">68</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref069">69</xref>] (reviewed in [<xref ref-type="bibr" rid="pbio.3000717.ref070">70</xref>]). This difference could be attributable to multiple factors, including the limited selectivity of the GluN2B inhibitors [<xref ref-type="bibr" rid="pbio.3000717.ref071">71</xref>], differential actions of GluN2B inhibitors on di- and triheteromeric NMDARs [<xref ref-type="bibr" rid="pbio.3000717.ref061">61</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref062">62</xref>], and influences of GluN2B inhibitors on glutamate dissociation rate [<xref ref-type="bibr" rid="pbio.3000717.ref039">39</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref072">72</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref073">73</xref>].</p>
<p>Notably, a recent study employing single-neuron gene knockout (KO) has reported that GluN2A or GluN2B is not critically required for ionotropic or non-ionotropic (not involving NMDAR-dependent ion flow [<xref ref-type="bibr" rid="pbio.3000717.ref074">74</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref076">76</xref>]) NMDAR-dependent LTD, whereas GluN1 is required for non-ionotropic NMDAR-dependent LTD [<xref ref-type="bibr" rid="pbio.3000717.ref077">77</xref>]. It is thus possible that the reduced levels of GluN1 in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice may contribute to the reduced LTD at SC-CA1 synapses. However, the previous single-neuron KO study employed AAV-dependent gene KO at the mouse age of P0–1, leaving GluN2B expression and function at embryonic stages unaffected. In addition, the single-neuron KO study would lead to homozygous (not heterozygous) <italic>Grin2b</italic> deletion, which might also affect the results.</p>
</sec>
<sec id="sec015">
<title>GluN2B-C456Y and behaviors</title>
<p><italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice showed moderately enhanced self-grooming, a core ASD-like behavior, in home cages with bedding, but normal self-grooming in a novel chamber without bedding, suggesting that these mice display moderately enhanced self-grooming that is suppressed by a novel environment. Moreover, enhanced self-grooming in home cages with bedding was observed in adult but not juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, suggesting that repetitive self-grooming develops late in life in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice and thus is unlikely to be ameliorated by early D-cycloserine treatment.</p>
<p>Contrary to our expectations, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice showed normal social approach, social novelty recognition, and social interaction in three-chamber and direct social-interaction tests. In addition, these animals showed normal social communication (USVs) during courtship. Juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice also displayed normal social interaction in the juvenile play test and spent normal amounts of time with reunited mothers. It is possible, however, that the social tests and variables that we employed in the present study may not be sensitive enough to detect certain social deficits.</p>
<p>Both adult and juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice showed hypoactivity in the open-field test, suggesting that this phenotype is established early (in juvenile or earlier stages) and persist into adulthood. Adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice show anxiolytic-like behavior in the elevated plus-maze test but normal anxiety-like behaviors in open-field and light-dark tests. Juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice show anxiolytic-like behavior in the open-field test, suggesting that adult and juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice show normal or anxiolytic-like behaviors. In contrast, <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups display strongly increased USV calls upon mother separation, suggestive of anxiety-like behavior. Therefore, the anxiety-like behavior of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups seems to be rapidly weakened as these mice grow up, whereas self-grooming slowly develops at an adult stage, pointing to the contrasting trajectories of two important ASD-related phenotypes (anxiety-like behavior and self-grooming). How the early anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> pups is weakened or reversed as the pups grow into juveniles and adults remain unclear. This age-dependent reversal might reflect compensatory changes trying to overcome the over-activation of anxiety-related neural circuits. Although further details remain to be determined, our results are in line with the fact that anxiety is one of the key comorbidities of ASD [<xref ref-type="bibr" rid="pbio.3000717.ref046">46</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref078">78</xref>] and that many mouse models of ASD display anxiety-like behaviors [<xref ref-type="bibr" rid="pbio.3000717.ref042">42</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref079">79</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref080">80</xref>]. Notably, anxiolytic-like behavior has also been observed in mice lacking oxytocin [<xref ref-type="bibr" rid="pbio.3000717.ref081">81</xref>], implicated in ASD [<xref ref-type="bibr" rid="pbio.3000717.ref082">82</xref>].</p>
<p><italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (carrying conventional heterozygous <italic>Grin2b</italic> deletion) mice showed largely similar behaviors compared with those observed in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. Similar behaviors include hypoactivity in the open-field test and normal anxiety-like behavior in open-field and light-dark tests, but anxiolytic-like behavior of <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice in the elevated plus-maze was much weaker than that in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. Biochemically, <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice showed decreased levels of GluN2B but not GluN1 at P14 and P21, unlike the concomitant decreases in GluN2B and GluN1 in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice, which may lead to subtle differences in synaptic and behavioral dysfunctions in these two mouse lines.</p>
<p>The behavioral phenotypes of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice could not be compared with the symptoms of the human individual carrying GluN2B-C456Y mutation as they were minimally described in the previous study other than the fact that the mutation is a de novo mutation from a male individual with autism and intellectual disability [<xref ref-type="bibr" rid="pbio.3000717.ref012">12</xref>]. However, the abnormal behaviors (i.e., anxiolytic-like behavior) of the mutant mice are important biologically because spending more time in the center region of a novel open-field arena or in the open arms of the elevated plus-maze reflects behaviors that would pose a significant threat for the survival of a mouse in its natural environment, implicating substantial deficits in cognitive functions. The anxiolytic-like behavior may not reflect increased fear of a dark or closed environment, because these mice exhibited a normal preference for light and dark chambers in the light-dark test. In addition, the anxiolytic-like behavior of the mutant mice in the elevated plus-maze does not seem to involve suppressed cognition of the fact that a darker and closed place is generally safe at least based on their normal learning and memory in Morris water-maze and novel object–recognition tests.</p>
</sec>
<sec id="sec016">
<title>NMDAR function, LTD, and anxiolytic-like behavior</title>
<p>Importantly, our study suggests synaptic mechanisms that may be associated with the anxiolytic-like behavior, namely suppressed NMDAR functions and LFS-LTD at an early stage. In support of this hypothesis, early chronic D-cycloserine treatment of young <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice normalizes NMDAR function and LTD in juvenile <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice and anxiolytic-like behavior in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. In addition, late acute treatment of adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice with D-cycloserine has no effect on abnormal behaviors probably because GluN2B expression is decreased at adult stages, and NMDAR-dependent LTD is difficult to induce at adult stages likely due to the switch of GluN2B to GluN2A [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref083">83</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref084">84</xref>]. The effect of late chronic D-cycloserine treatment in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice could not be tested because the chronic treatment procedure seemed to increase anxiety levels in these mice, blunting the baseline difference between WT and mutant mice. In addition, we could not test whether the increased USV calls in the mutant pups are associated with the reduced NMDAR function because the time window for early D-cycloserine treatment (P7–16) fell behind that for pup USV testing (P4–12). Together, these results suggest that early correction of NMDAR function and NMDAR-dependent LTD in young mice leads to long-lasting improvement of anxiolytic-like behavior in adult mice. Early treatment seems to be particularly important, not only because it has long-lasting effects, eliminating the necessity of repeated drug administration, but also because the small time window during which treatment is efficient appears to occur only during early developmental stages. Indeed, LTD is known to be most prominent during an early period (approximately 2–3 weeks) of postnatal brain development in mice and becomes weaker as the brain progressively matures and the ratio of GluN2B/GluN2A expression decreases [<xref ref-type="bibr" rid="pbio.3000717.ref034">34</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref085">85</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref087">87</xref>].</p>
<p>Our findings are in line with the emerging concept that early and timely correction of key pathophysiological deficits in young mice is critical for the long-lasting and efficient rescue of synaptic and behavioral phenotypes in adult mice. For instance, early chronic fluoxetine treatment to restore reduced serotonin levels in young mice carrying a 15q11-13 duplication, a human ASD-risk mutation, has been shown to induce long-lasting normalization of serotonin levels and abnormal behaviors in adult mice [<xref ref-type="bibr" rid="pbio.3000717.ref088">88</xref>]. Similarly, <italic>Shank2</italic>-mutant mice show increased NMDAR function (in contrast to decreased NMDAR function in later stages) [<xref ref-type="bibr" rid="pbio.3000717.ref009">9</xref>], and early, but not late, chronic memantine treatment to suppress the abnormal NMDAR hyperfunction improves late synaptic and social phenotypes in <italic>Shank2</italic>-mutant mice [<xref ref-type="bibr" rid="pbio.3000717.ref089">89</xref>].</p>
<p>Our data indicate that LFS-LTD are similarly decreased in the hippocampus and mPFC. These results suggest that the decreased NMDAR function and LFS-LTD in the hippocampus may represent a proxy for changes occurring in other brain regions and that decreased NMDAR function and LFS-LTD in many brain areas, additional to the hippocampus, could contribute to the behavioral changes (i.e., anxiolytic-like behavior) observed in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice. In line with this idea, <italic>Grin2b</italic> is widely expressed in the brain [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>], and anxiety-like behavior has been associated with various brain regions, including the hippocampus, anterior cingulate cortex, lateral septum, bed nuclei of the stria terminalis, paraventricular nucleus, and basolateral amygdala [<xref ref-type="bibr" rid="pbio.3000717.ref090">90</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref097">97</xref>].</p>
<p>Lastly, GluN2B-C456Y is a strong ASD-risk mutation [<xref ref-type="bibr" rid="pbio.3000717.ref012">12</xref>]. How might the abnormal synaptic and behavioral phenotypes of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice be related to ASD pathophysiology? GluN2B-containing NMDARs that mediate large calcium influx are strongly expressed during early brain developmental stages to promote synapse and neuronal maturation through mechanisms, including posttranslational modification and gene expression [<xref ref-type="bibr" rid="pbio.3000717.ref005">5</xref>]. Therefore, the decreased levels of GluN2B and GluN2B-containing NMDARs in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice would suppress these critical molecular and cellular early events. In addition, NMDAR-dependent LTD during early brain development is well known to sharpen neuronal circuits by promoting weakening of less active synapses and strengthening of more active synapses through redistribution of synaptic protein resources between these synapses [<xref ref-type="bibr" rid="pbio.3000717.ref083">83</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref084">84</xref>]. Therefore, reduced LTD in the developing brain of young <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice would suppress LTD-dependent synapse-pruning and circuit-sharpening processes, leading to brain malfunctions and abnormal behaviors. This prediction, based on in vivo results, might apply not only to GluN2B-C456Y-related cases of ASD [<xref ref-type="bibr" rid="pbio.3000717.ref001">1</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref011">11</xref>–<xref ref-type="bibr" rid="pbio.3000717.ref016">16</xref>] but also to various GRIN2B-related brain dysfunctions, including developmental delay, intellectual disability, attention-deficit/hyperactivity disorder, epilepsy, schizophrenia, obsessive-compulsive disorder, and encephalopathy [<xref ref-type="bibr" rid="pbio.3000717.ref015">15</xref>,<xref ref-type="bibr" rid="pbio.3000717.ref017">17</xref>]. How these predicted changes manifest into synaptic and circuit properties in the mutant brain remains to be determined. Previous studies have shown that NMDAR antagonists, including the GluN2B-specific antagonist ifenprodil, can induce anxiolytic-like behaviors in both humans and experimental animals [<xref ref-type="bibr" rid="pbio.3000717.ref098">98</xref>]. However, a decrease in NMDAR function in the adult mutant brain is an unlikely possibility because both acute and chronic D-cycloserine treatment failed to rescue the anxiolytic-like behavior in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</p>
<p>In conclusion, the heterozygous ASD-risk mutation, GluN2B-C456Y, leads to decreased GluN2B protein levels, diminished currents of GluN2B-containing NMDARs, and reduced NMDAR-dependent LTD in young mice, as well as abnormal, anxiolytic-like behavior in adult mice. In addition, early D-cycloserine treatment of young mutant mice correcting NMDAR function and NMDAR-dependent LTD leads to long-lasting improvement of anxiolytic-like behaviors in adult mice.</p>
</sec>
</sec>
<sec id="sec017" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec018">
<title>Ethics statement</title>
<p>All animals were bred and maintained according to the Requirements of Animal Research at KAIST and all procedures were approved by the Committees of Animal Research at KAIST (KA2016-31).</p>
</sec>
<sec id="sec019">
<title>Animals</title>
<p>Grin2b knock-in mice under the genetic background of C57BL/6J carrying C456Y mutation in exon 6 with Frt sites and cassette were designed and generated by Biocytogen (<italic>Grin2b</italic><sup><italic>+/cassette</italic></sup>, <xref ref-type="supplementary-material" rid="pbio.3000717.s001">S1A Fig</xref>). To remove the neomycin cassette, <italic>Grin2b</italic><sup><italic>+/cassette</italic></sup> mice were crossed with Protamine-Flp mice (C57BL/6J), which yielded floxed heterozygote mice (<italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup>).</p>
</sec>
<sec id="sec020">
<title>Statistical analysis</title>
<p>Statistical analyses were performed using Prism GraphPad 7 and SigmaPlot 11. The data with nonparametric distribution were analyzed by Mann-Whitney test, and those with parametric distribution were analyzed by Student <italic>t</italic> test. If the data are parametric but have significant difference in variance in the F-test, Welch’s correction was used. Including gender, age, and number of mice, all the details of the statistical analyses are described in <xref ref-type="supplementary-material" rid="pbio.3000717.s013">S1 Data</xref>.</p>
</sec>
<sec id="sec021">
<title>Additional materials and methods</title>
<p>Details on other methods, including those for experiments on recombinant GluN1/GluN2B receptors, can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s014">S2 Data</xref>.</p>
</sec>
<sec id="sec022">
<title>Numerical data</title>
<p>The numerical data used in all figures can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>.</p>
</sec>
<sec id="sec023">
<title>Original images for blots and gels</title>
<p>The original images for blots and gels can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s016">S4 Data</xref>.</p>
</sec>
</sec>
<sec id="sec024" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pbio.3000717.s001">
<label>S1 Fig</label>
<caption>
<title>Structural modeling predicts that the GluN2B-C456Y mutation disrupts a disulfide bond between the ATD and LBD.</title>
<p>(A and B) Molecular modeling of the GluN2B-C456Y protein in complex with the GluN1 subunit of NMDARs. Note that the two cysteine residues in patch 1 of the LBD and patch 2 of the ATD in the WT GluN2B protein form a disulfide bond that strengthens the interaction between LBD and ATD, a bond that is disrupted by the GluN2B-C456Y mutation in patch 1 of the LBD. ATD, amino-terminal domain; LBD, ligand-binding domain; NMDAR, N-methyl-D-aspartate receptor; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s001.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s002">
<label>S2 Fig</label>
<caption>
<title>The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties.</title>
<p>(A) The GluN2B-C456Y mutation strongly decreases diheteromeric GluN1/GluN2B NMDAR currents in <italic>Xenopus</italic> oocytes. Note that the amount of the mutant currents is &lt;1% of the WT currents, despite the fact that mutant currents were recorded 1 day later than WT (3 and 2 days following oocyte injection, respectively). <italic>n</italic> = 73 oocytes for WT (5.70 ± 0.61 μA) and 59 oocytes for C456Y (0.039 ± 0.004 μA), ***<italic>P</italic> &lt; 0.001, Mann-Whitney. (B) The GluN2B-C456Y mutation increases maximal open probability, as assessed by measuring MK-801 inhibition kinetics. <italic>n</italic> = 22 oocytes for WT (1 ± 0.03, relative τ<sub>on</sub>) and 19 oocytes for C456Y (0.71 ± 0.05, relative τ<sub>on</sub>), ***<italic>P</italic> &lt; 0.001, Mann-Whitney. (C) The GluN2B-C456Y mutation reduces the sensitivity to extracellular protons. <italic>n</italic> = 4 oocytes for WT (pH IC<sub>50</sub> = 7.49 ± 0.016) and 5 oocytes for C456Y (pH IC<sub>50</sub> = 7.11 ± 0.0075), *<italic>P</italic> = 0.016, Mann-Whitney. (D) The GluN2B-C456Y mutation decreases the spermine-dependent potentiation. <italic>n</italic> = 5 oocytes for WT (9.45 ± 0.51, spermine potentiation) and 4 oocytes for C456Y (2.83 ± 0.077, spermine potentiation),*<italic>P</italic> = 0.016, Mann-Whitney. (E) The GluN2B-C456Y mutation does not affect the sensitivity to glutamate. <italic>n</italic> = 4 oocytes for WT (EC<sub>50</sub> = 1.75 ± 0.04 μM) and 3 oocytes for C456Y (EC<sub>50</sub> = 1.86 ± 0.02 μM), <italic>P</italic> = 0.23, Mann-Whitney. (F) The GluN2B-C456Y mutation decreases the sensitivity to glycine. <italic>n</italic> = 4 oocytes for WT (EC<sub>50</sub> = 0.38 ± 0.017 μM) and 9 oocytes for C456Y (EC<sub>50</sub> = 1.13 ± 0.049 μM), **<italic>P</italic> = 0.007, Mann-Whitney. (G) The GluN2B-C456Y mutation has minimal effect on the sensitivity to extracellular zinc. <italic>n</italic> = 11 oocytes for WT (IC<sub>50</sub> = 0.68 ± 0.07 μM) and 11 oocytes for C456Y (IC<sub>50</sub> = 0.97 ± 0.1 μM), ***<italic>P</italic> &lt; 0.001, Mann-Whitney. (H) D-cycloserine is a partial agonist at GluN2B-C456Y mutant receptors. Currents recorded in 100 μM glutamate plus 100 μM D-cycloserine were normalized to currents recorded in 100 μM glutamate + 100 μM glycine (no D-cycloserine). <italic>n</italic> = 9 oocytes for WT (relative current: 0.57 ± 0.005) and 9 oocytes for C456Y (relative current: 0.40 ± 0.006), ***<italic>P</italic> &lt; 0.001, Mann-Whitney. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. EC<sub>50</sub>, half maximal effective concentration; IC<sub>50</sub>, half maximal inhibitory concentration; NMDAR, N-methyl-D-aspartate receptor; ns, not significant; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s002.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s003">
<label>S3 Fig</label>
<caption>
<title>Knock-in strategy and PCR genotyping for the GluN2B-C456Y mutation in mice.</title>
<p>(A) Knock-in strategy for the GluN2B-C456Y mutation in mice. WT exon 6 was replaced with a mutant exon 6 containing the C456Y mutation. (B) PCR genotyping of homozygous (“Homo”) and HT KI mice. Ex, exon; Frt, flippase target site; Homo, homozygous; HT, heterozygous; KI, knock-in; Neo, neomycin gene; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s003.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s004">
<label>S4 Fig</label>
<caption>
<title>Decreased GluN2B and GluN1 protein levels, but normal <italic>Grin2b</italic> and <italic>Grin1</italic> mRNA levels, in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A) Crude synaptosomal fractions from the <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> brain at multiple developmental stages (E20, P14, P21, P28, and P56) were immunoblotted with the indicated antibodies. For quantification (bar graphs), average levels of GluN1, Glu2A, and Glu2B proteins from <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice were normalized to those from WT mice. <italic>n</italic> = 4 mice for WT and HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, Student <italic>t</italic> test. (B) Normal levels of <italic>Grin2b</italic> and <italic>Grin1</italic> (encoding GluN1) mRNAs in WT, HT, and homozygous (“Homo”) KI embryos (E20), as indicated by the results of RT-qPCR reactions targeting Grin2b mRNA exons 3, 4, 11, or 14, and Grin1 mRNA exons 3, 7, or 12. <italic>n</italic> = 4 mice for WT, 4 for HT, and 3 for Homo, one-way ANOVA with Tukey’s test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. E, embryonic day; HT, heterozygous; KI, knock-in; ns, not significant; P, postnatal day; RT-qPCR, real-time quantitative PCR; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s004.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s005">
<label>S5 Fig</label>
<caption>
<title>Spontaneous and evoked synaptic transmission at excitatory and inhibitory synapses, as well as neuronal excitability, are normal in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> hippocampal CA1 neurons.</title>
<p>(A) Normal mEPSCs in CA1 neurons of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P18–20). <italic>n</italic> = 15 neurons from 3 mice for WT and 15 (3) for HT, Mann-Whitney test (frequency) and Student <italic>t</italic> test (amplitude). (B) Normal mIPSCs in CA1 neurons of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P21–23). <italic>n</italic> = 15 (3) for WT and HT, Student <italic>t</italic> test. (C) Normal sEPSCs in CA1 neurons of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P22–24). <italic>n</italic> = 15 (3) for WT and 14 (4) for HT, Mann-Whitney test. (D) Normal sIPSCs in CA1 neurons of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P22–24). <italic>n</italic> = 13 (3) for WT and 18 (4) for HT, Mann-Whitney test (frequency) and Student <italic>t</italic> test (amplitude). (E) Normal ratio of evoked IPSCs over evoked EPSCs in the CA1 region of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P20–22). <italic>n</italic> = 8 (4) for WT and 8 (3) for HT, Mann-Whitney test. (F) Normal neuronal excitability in CA1 neurons of <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P21–23), as indicated by the current-firing relationship. <italic>n</italic> = 13 (3) for WT and 13 (4) for HT, two-way ANOVA. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. EPSC, excitatory postsynaptic current; HT, heterozygous; IPSC, inhibitory postsynaptic current; mEPSC, miniature EPSC; mIPSC, miniature IPSC; ns, not significant; P, postnatal day; sEPSC, spontaneous EPSC; sIPSC, spontaneous IPSC; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s005.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s006">
<label>S6 Fig</label>
<caption>
<title>Normal spatial and recognition learning and memory in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A–E) Normal spatial learning and memory in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P90–114) in the learning (A) and probe (B–E) phases of the initial (A–C) and reversal (A, D, E) sessions of the Morris water maze, as shown by time taken to escape to the platform, percent of time spent in target quadrant, and number of crossing over the former platform location. <italic>n</italic> = 12 mice for WT and HT, two-way ANOVA with Sidak’s test and Student <italic>t</italic> test. (F) Normal novel object–recognition memory in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P70–80), as shown by the percent of time spent exploring a novel object relative to a familiar object. <italic>n</italic> = 12 mice for WT and HT, Student <italic>t</italic> test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. HT, heterozygous; ns, not significant; P, postnatal day; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s006.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s007">
<label>S7 Fig</label>
<caption>
<title>Normal social interaction and communication and moderately enhanced self-grooming in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A–H) Normal social approach and social novelty recognition in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P79–80) in the three-chamber test under both bright-light and dark conditions, as shown by time spent sniffing the target and time spent in the chamber with the target. <italic>n</italic> = 8 mice for WT and HT (except for <italic>n</italic> = 7 for HT for social novelty recognition), **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Sidak’s test. (I–K) Normal social interaction in freely moving <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P62–89) in the direct social-interaction test, as shown by time spent in nose-to-nose sniffing or following and total time spent in social interaction (sniffing, following, and other social interactions). <italic>n</italic> = 11 mice for WT and 13 for HT, Student <italic>t</italic> test (except for Mann-Whitney test for following). (L–N) Normal courtship USVs in male <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P74–101) upon encountering a novel female mouse, as shown by the number of calls, duration of each call, and latency to the first call. <italic>n</italic> = 21 mice for WT and 17 for HT, Student <italic>t</italic> test (except for Mann-Whitney test for latency to first call). (O–P) Enhanced repetitive self-grooming (but normal digging) by <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P68–88) in home cages with bedding, but normal self-grooming in a novel chamber without bedding, as shown by time spent self-grooming (or digging). <italic>n</italic> = 21 mice for WT and 17 for HT for self-grooming in home cages with bedding, <italic>n</italic> = 16 mice for WT and HT for self-grooming in a novel chamber without bedding, *<italic>P</italic> &lt; 0.05, Student <italic>t</italic> test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. HT, heterozygous; ns, not significant; P, postnatal day; USV, ultrasonic vocalization; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s007.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s008">
<label>S8 Fig</label>
<caption>
<title><italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice display decreased GluN2B levels and hypoactivity and anxiolytic-like behavior, similar to <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A and B) Decreased levels of the GluN2B, but not GluN1 or GluN2A, protein in the <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice brain. Whole-brain total lysates from <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice at P14 and P21 were immunoblotted with anti-GluN1/2A/2B antibodies. For quantification, average levels of GluN1/2A/2B proteins from <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice were normalized to those from WT mice. <italic>n</italic> = 4 mice for WT and HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, Student <italic>t</italic> test. (C–F) Hypoactivity and normal anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P61–71) in the open-field test, as shown by distance moved and time spent in the center region of the open-field arena. <italic>n</italic> = 16 mice for WT and 14 for HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Sidak’s test and Student <italic>t</italic> test. (G–J) Anxiolytic-like behavior in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P65–75) in the elevated plus-maze, as shown by the number of entries into and time spent in open/closed arms. <italic>n</italic> = 16 mice (WT) and 14 (HT), ***<italic>P</italic> &lt; 0.001, Student <italic>t</italic> test. (K) Normal anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P68–78) in the light-dark test, as shown by time spent in the light chamber. <italic>n</italic> = 16 mice (WT) and 14 (HT), Mann-Whitney test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. HT, heterozygous; ns, not significant; P, postnatal day; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s008.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s009">
<label>S9 Fig</label>
<caption>
<title>Normal social interaction and communication, repetitive behavior, and object memory in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice.</title>
<p>(A–H) Normal social approach and social novelty recognition in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P75–85) in the three-chamber test under both bright-light and dark conditions, as shown by time spent sniffing the target and time spent in the chamber with the target. <italic>n</italic> = 8 mice for WT and 7 for HT, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Sidak’s test. (I–K) Normal courtship USVs in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P77–87) upon encountering a novel female mouse, as shown by the number of calls, duration of each call, and latency to the first call. <italic>n</italic> = 16 for WT and 14 for HT, Student <italic>t</italic> test except Mann-Whitney test for latency to first all. (L and M) Normal repetitive self-grooming and digging in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P77–87) in home cages with bedding, as shown by time spent self-grooming or digging. <italic>n</italic> = 16 (WT) and 14 (HT), Mann-Whitney test. (N) Normal novel object–recognition memory in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P63–73), as shown by the percent of time spent exploring a novel object relative to a familiar object. <italic>n</italic> = 16 (WT) and 14 (HT), Student <italic>t</italic> test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. HT, heterozygous; ns, not significant; P, postnatal day; USV, ultrasonic vocalization; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s009.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s010">
<label>S10 Fig</label>
<caption>
<title>Normal social interaction and repetitive behavior in <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles.</title>
<p>(A and B) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles (P22–24) show normal behaviors in the maternal-homing test, as shown by the time spent with the reunited mother. Note that these mice showed normal exploration of the bedding materials from previous home cages (“Home”) suggestive of normal olfactory function; it is unclear why these mice prefer to explore the new corner (“New”). <italic>n</italic> = 24 mice for WT and 20 for HT, *<italic>P</italic> &lt; 0.05, ***P &lt; 0.001, two-way ANOVA with Sidak’s test. (C) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles (P28–20) show normal social interaction in the juvenile play test, as shown by the total time spent in social interaction (nose-to-nose sniffing, following, and other social interactions). <italic>n</italic> = 9 pairs for WT and 5 pairs for HT, Student <italic>t</italic> test. (D and E) <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> juveniles (P24–26) show normal repetitive self-grooming and digging in home cages with bedding, as shown by time spent self-grooming or digging. <italic>n</italic> = 24 mice for WT and 20 for HT, Mann-Whitney test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. HT, heterozygous; ns, not significant; P, postnatal day; WT, wild type.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s010.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s011">
<label>S11 Fig</label>
<caption>
<title>Early DCS rescues LFS-LTD and has no effect on the hypoactivity or anxiety-like behavior in <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice.</title>
<p>(A) Experimental strategy for chronic, oral DCS treatment (40 mg/kg), twice daily for 10 days (P7–16), in young <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice followed by LTD measurements in juvenile mice (P17–21) and behavioral tests (OFT and EPM) in adult mice (&gt;P56). (B) Early chronic DCS treatment normalizes LFS-LTD at SC-CA1 synapses in juvenile <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P17–20). <italic>n</italic> = 14 mice (6) for WT_V (78.0% ± 4.1%), 15 (5) for WT_D (85.2% ± 4.2%), 17 (6) for HT_V (96.9% ± 4.5%), 14 (5) for HT_D (79.6% ± 3.7%), *<italic>P</italic> &lt; 0.05, two-way ANOVA with Tukey’s test. (C) Early chronic DCS treatment has no effect on the hypoactivity in adult <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P56–62). <italic>n</italic> = 11 mice for WT_D, 12 for WT_D, 9 for HT_V, 11 for HT_D, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Tukey’s test. (D) Early chronic DCS treatment has no effect on the anxiety-like behavior in adult <italic>Grin2b</italic><sup><italic>+/–</italic></sup>mice (P58–76), as shown by closed-arm time and open-arm entry/time. Note, however, that the early chronic drug treatment procedure (P7–16; twice a day for 10 days; oral) seems to modestly increase anxiety levels in the mutant mice, blunting the baseline difference in the closed-arm entry between WT-V and HT-V (see also panel G in <xref ref-type="supplementary-material" rid="pbio.3000717.s008">S8 Fig</xref>), making it impossible to assess the effect of DCS on this value. <italic>n</italic> = 11 mice for WT_D, 12 for WT_D, 9 for HT_V, 11 for HT_D, two-way ANOVA with Tukey’s test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. DCS, D-cycloserine; EPM, elevated plus-maze; HT, heterozygous; HT_D, heterozygous with DCS; HT_V, heterozygous with vehicle; LFS, low-frequency stimulation; LTD, long-term depression; ns, not significant; OFT, open-field test; P, postnatal day; SC-CA1, Schaffer collateral-CA1 pyramidal; WT, wild type; WT_D, WT with DCS; WT_V, WT with vehicle.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s011.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s012">
<label>S12 Fig</label>
<caption>
<title>Late chronic DCS treatment has no effect on anxiolytic-like behavior or hypoactivity in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice.</title>
<p>(A–E) Late chronic oral DCS treatment (40 mg/kg; twice daily for 10 days) in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P57–66) does not affect anxiolytic-like behavior in the EPM. Note, however, that the chronic drug treatment procedure (oral drug administration twice a day for 10 days using a restrainer, unlike the pup situation in which pups were gently grabbed) seems to substantially increase anxiety levels in the mutant mice, blunting the baseline difference in EPM variables between WT-V and HT-V (see also <xref ref-type="fig" rid="pbio.3000717.g003">Fig 3E–3H</xref> and <xref ref-type="fig" rid="pbio.3000717.g004">Fig 4F–4I</xref>), making it impossible to assess the effect of DCS on these values. <italic>n</italic> = 10 mice for WT_D, 11 for WT_D, 11 for HT_V, 12 for HT_D, two-way ANOVA with Tukey’s test. (F–I) Late chronic oral DCS treatment (40 mg/kg; twice daily for 10 days) in adult <italic>Grin2b</italic><sup><italic>+/C456Y</italic></sup> mice (P57–66) does not affect hypoactivity in the OFT. <italic>n</italic> = 10 mice for WT_D, 11 for WT_D, 11 for HT_V, 12 for HT_D, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, two-way ANOVA with Tukey’s test. The numerical data underlying this figure can be found in <xref ref-type="supplementary-material" rid="pbio.3000717.s015">S3 Data</xref>. DCS, D-cycloserine; EPM, elevated plus-maze; HT, heterozygous; HT_D, heterozygous with DCS; HT_V, heterozygous with vehicle; ns, not significant; OFT, open-field test; P, postnatal day; WT, wild type; WT_D, WT with DCS; WT_V, WT with vehicle.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pbio.3000717.s012.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s013">
<label>S1 Data</label>
<caption>
<title>Age and sex of mice used in the study and statistical methods and results.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pbio.3000717.s013.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s014">
<label>S2 Data</label>
<caption>
<title>Supplementary methods.</title>
<p>(DOCX)</p>
</caption>
<media xlink:href="pbio.3000717.s014.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s015">
<label>S3 Data</label>
<caption>
<title>Numerical data underlying main figures (Figs <xref ref-type="fig" rid="pbio.3000717.g001">1</xref>–<xref ref-type="fig" rid="pbio.3000717.g005">5</xref>) and supplementary figures (<xref ref-type="supplementary-material" rid="pbio.3000717.s002">S2</xref> and <xref ref-type="supplementary-material" rid="pbio.3000717.s004">S4</xref>–<xref ref-type="supplementary-material" rid="pbio.3000717.s012">S12 Fig</xref>).</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pbio.3000717.s015.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pbio.3000717.s016">
<label>S4 Data</label>
<caption>
<title>Uncropped immunoblot and gels images for <xref ref-type="fig" rid="pbio.3000717.g001">Fig 1B</xref>, <xref ref-type="supplementary-material" rid="pbio.3000717.s003">S3B Fig</xref>, <xref ref-type="supplementary-material" rid="pbio.3000717.s004">S4A Fig</xref>, <xref ref-type="supplementary-material" rid="pbio.3000717.s008">S8A Fig</xref> and <xref ref-type="supplementary-material" rid="pbio.3000717.s008">S8B Fig</xref>.</title>
<p>(PDF)</p>
</caption>
<media xlink:href="pbio.3000717.s016.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We would like to thank Dr. Yeonseung Chung in the Department of Mathematical Sciences at KAIST for help with the statistical analyses.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AMPA</term>
<def>
<p>alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</p>
</def>
</def-item>
<def-item>
<term>AMPAR</term>
<def>
<p>AMPA receptor</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p>autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>ATD</term>
<def>
<p>amino-terminal domain</p>
</def>
</def-item>
<def-item>
<term>CaMKII</term>
<def>
<p>Ca<sup>2+</sup>/calmodulin dependent protein kinase II</p>
</def>
</def-item>
<def-item>
<term>DHPG</term>
<def>
<p>dihydroxyphenylglycine</p>
</def>
</def-item>
<def-item>
<term>E</term>
<def>
<p>embryonic day</p>
</def>
</def-item>
<def-item>
<term>EM</term>
<def>
<p>electron microscopic</p>
</def>
</def-item>
<def-item>
<term>EPSC</term>
<def>
<p>excitatory postsynaptic current</p>
</def>
</def-item>
<def-item>
<term>fEPSP</term>
<def>
<p>field excitatory postsynaptic potential</p>
</def>
</def-item>
<def-item>
<term>Grin1</term>
<def>
<p><italic>Glutamate receptor</italic>, <italic>ionotropic</italic>, <italic>NMDA1</italic></p>
</def>
</def-item>
<def-item>
<term>Grin2b</term>
<def>
<p><italic>Glutamate receptor</italic>, <italic>ionotropic</italic>, <italic>NMDA2B</italic></p>
</def>
</def-item>
<def-item>
<term>HEK-293</term>
<def>
<p>human embryonic kidney 293</p>
</def>
</def-item>
<def-item>
<term>HFS</term>
<def>
<p>high-frequency stimulation</p>
</def>
</def-item>
<def-item>
<term>i.p.</term>
<def>
<p>intraperitoneal</p>
</def>
</def-item>
<def-item>
<term>IPSC</term>
<def>
<p>inhibitory postsynaptic current</p>
</def>
</def-item>
<def-item>
<term>KO</term>
<def>
<p>knockout</p>
</def>
</def-item>
<def-item>
<term>LBD</term>
<def>
<p>ligand-binding domain</p>
</def>
</def-item>
<def-item>
<term>LFS</term>
<def>
<p>low-frequency stimulation</p>
</def>
</def-item>
<def-item>
<term>LTD</term>
<def>
<p>long-term depression</p>
</def>
</def-item>
<def-item>
<term>LTP</term>
<def>
<p>long-term potentiation</p>
</def>
</def-item>
<def-item>
<term>mEPSC</term>
<def>
<p>miniature EPSC</p>
</def>
</def-item>
<def-item>
<term>mGluR</term>
<def>
<p>metabotropic glutamate receptor</p>
</def>
</def-item>
<def-item>
<term>mIPSC</term>
<def>
<p>miniature IPSC</p>
</def>
</def-item>
<def-item>
<term>mPFC</term>
<def>
<p>medial prefrontal cortex</p>
</def>
</def-item>
<def-item>
<term>NMDA</term>
<def>
<p>N-methyl-D-aspartate</p>
</def>
</def-item>
<def-item>
<term>NMDAR</term>
<def>
<p>NMDA receptor</p>
</def>
</def-item>
<def-item>
<term>ns</term>
<def>
<p>not significant</p>
</def>
</def-item>
<def-item>
<term>P</term>
<def>
<p>postnatal day</p>
</def>
</def-item>
<def-item>
<term>PSD</term>
<def>
<p>postsynaptic density</p>
</def>
</def-item>
<def-item>
<term>SC-CA1</term>
<def>
<p>Schaffer collateral-CA1 pyramidal</p>
</def>
</def-item>
<def-item>
<term>sEPSC</term>
<def>
<p>spontaneous EPSC</p>
</def>
</def-item>
<def-item>
<term>SFARI</term>
<def>
<p>Simons Foundation Autism Research Initiative</p>
</def>
</def-item>
<def-item>
<term>sIPSC</term>
<def>
<p>spontaneous IPSC</p>
</def>
</def-item>
<def-item>
<term>TBS</term>
<def>
<p>theta burst stimulation</p>
</def>
</def-item>
<def-item>
<term>USV</term>
<def>
<p>ultrasonic vocalization</p>
</def>
</def-item>
<def-item>
<term>WT</term>
<def>
<p>wild type</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pbio.3000717.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Abrahams</surname><given-names>BS</given-names></name>, <name><surname>Arking</surname><given-names>DE</given-names></name>, <name><surname>Campbell</surname><given-names>DB</given-names></name>, <name><surname>Mefford</surname><given-names>HC</given-names></name>, <name><surname>Morrow</surname><given-names>EM</given-names></name>, <name><surname>Weiss</surname><given-names>LA</given-names></name>, <etal>et al</etal>
<article-title>SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs)</article-title>. <source/>Molecular autism. <year>2013</year>;<volume>4</volume>(<issue>1</issue>):<fpage>36</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-36</pub-id>
<pub-id pub-id-type="pmid">24090431</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>EJ</given-names></name>, <name><surname>Choi</surname><given-names>SY</given-names></name>, <name><surname>Kim</surname><given-names>E</given-names></name>. <article-title>NMDA receptor dysfunction in autism spectrum disorders</article-title>. <source/>Curr Opin Pharmacol. <year>2015</year>;<volume>20</volume>:<fpage>8</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2014.10.007</pub-id> .<pub-id pub-id-type="pmid">25636159</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref003">
<label>3</label>
<mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>KB</given-names></name>, <name><surname>Yi</surname><given-names>F</given-names></name>, <name><surname>Perszyk</surname><given-names>RE</given-names></name>, <name><surname>Furukawa</surname><given-names>H</given-names></name>, <name><surname>Wollmuth</surname><given-names>LP</given-names></name>, <name><surname>Gibb</surname><given-names>AJ</given-names></name>, <etal>et al</etal>
<article-title>Structure, function, and allosteric modulation of NMDA receptors</article-title>. <source/>The Journal of general physiology. <year>2018</year>;<volume>150</volume>(<issue>8</issue>):<fpage>1081</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.201812032</pub-id>
<pub-id pub-id-type="pmid">30037851</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref004">
<label>4</label>
<mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>S</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Allosteric modulators of NMDA receptors: multiple sites and mechanisms</article-title>. <source/>Current opinion in pharmacology. <year>2015</year>;<volume>20</volume>:<fpage>14</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2014.10.009</pub-id> .<pub-id pub-id-type="pmid">25462287</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Paoletti</surname><given-names>P</given-names></name>, <name><surname>Bellone</surname><given-names>C</given-names></name>, <name><surname>Zhou</surname><given-names>Q</given-names></name>. <article-title>NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</article-title>. <source/>Nature reviews Neuroscience. <year>2013</year>;<volume>14</volume>(<issue>6</issue>):<fpage>383</fpage>–<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3504</pub-id> .<pub-id pub-id-type="pmid">23686171</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Lussier</surname><given-names>MP</given-names></name>, <name><surname>Sanz-Clemente</surname><given-names>A</given-names></name>, <name><surname>Roche</surname><given-names>KW</given-names></name>. <article-title>Dynamic Regulation of N-Methyl-d-aspartate (NMDA) and alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors by Posttranslational Modifications</article-title>. <source/>The Journal of biological chemistry. <year>2015</year>;<volume>290</volume>(<issue>48</issue>):<fpage>28596</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R115.652750</pub-id>
<pub-id pub-id-type="pmid">26453298</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref007">
<label>7</label>
<mixed-citation publication-type="journal"><name><surname>Lau</surname><given-names>CG</given-names></name>, <name><surname>Zukin</surname><given-names>RS</given-names></name>. <article-title>NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders</article-title>. <source/>Nature reviews Neuroscience. <year>2007</year>;<volume>8</volume>(<issue>6</issue>):<fpage>413</fpage>–<lpage>26</lpage>. nrn2153 [pii] <pub-id pub-id-type="doi">10.1038/nrn2153</pub-id> .<pub-id pub-id-type="pmid">17514195</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Chung</surname><given-names>W</given-names></name>, <name><surname>Choi</surname><given-names>SY</given-names></name>, <name><surname>Lee</surname><given-names>E</given-names></name>, <name><surname>Park</surname><given-names>H</given-names></name>, <name><surname>Kang</surname><given-names>J</given-names></name>, <name><surname>Park</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression</article-title>. <source/>Nature neuroscience. <year>2015</year>
<pub-id pub-id-type="doi">10.1038/nn.3927</pub-id> .<pub-id pub-id-type="pmid">25622145</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref009">
<label>9</label>
<mixed-citation publication-type="journal"><name><surname>Won</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>HR</given-names></name>, <name><surname>Gee</surname><given-names>HY</given-names></name>, <name><surname>Mah</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>JI</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function</article-title>. <source/>Nature. <year>2012</year>;<volume>486</volume>(<issue>7402</issue>):<fpage>261</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nature11208</pub-id> .<pub-id pub-id-type="pmid">22699620</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Blundell</surname><given-names>J</given-names></name>, <name><surname>Blaiss</surname><given-names>CA</given-names></name>, <name><surname>Etherton</surname><given-names>MR</given-names></name>, <name><surname>Espinosa</surname><given-names>F</given-names></name>, <name><surname>Tabuchi</surname><given-names>K</given-names></name>, <name><surname>Walz</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior</article-title>. <source/>The Journal of neuroscience. <year>2010</year>;<volume>30</volume>(<issue>6</issue>):<fpage>2115</fpage>–<lpage>29</lpage>. 30/6/2115 [pii] <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4517-09.2010</pub-id> .<pub-id pub-id-type="pmid">20147539</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Myers</surname><given-names>RA</given-names></name>, <name><surname>Casals</surname><given-names>F</given-names></name>, <name><surname>Gauthier</surname><given-names>J</given-names></name>, <name><surname>Hamdan</surname><given-names>FF</given-names></name>, <name><surname>Keebler</surname><given-names>J</given-names></name>, <name><surname>Boyko</surname><given-names>AR</given-names></name>, <etal>et al</etal>
<article-title>A population genetic approach to mapping neurological disorder genes using deep resequencing</article-title>. <source/>PLoS Genet. <year>2011</year>;<volume>7</volume>(<issue>2</issue>):<fpage>e1001318</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1001318</pub-id> PubMed Central PMCID: PMC3044677. <pub-id pub-id-type="pmid">21383861</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>O'Roak</surname><given-names>BJ</given-names></name>, <name><surname>Vives</surname><given-names>L</given-names></name>, <name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>Egertson</surname><given-names>JD</given-names></name>, <name><surname>Stanaway</surname><given-names>IB</given-names></name>, <name><surname>Phelps</surname><given-names>IG</given-names></name>, <etal>et al</etal>
<article-title>Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders</article-title>. <source/>Science. <year>2012</year>;<volume>338</volume>(<issue>6114</issue>):<fpage>1619</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1126/science.1227764</pub-id>
<pub-id pub-id-type="pmid">23160955</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>De Rubeis</surname><given-names>S</given-names></name>, <name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Goldberg</surname><given-names>AP</given-names></name>, <name><surname>Poultney</surname><given-names>CS</given-names></name>, <name><surname>Samocha</surname><given-names>K</given-names></name>, <name><surname>Cicek</surname><given-names>AE</given-names></name>, <etal>et al</etal>
<article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>. <source/>Nature. <year>2014</year>;<volume>515</volume>(<issue>7526</issue>):<fpage>209</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/nature13772</pub-id>
<pub-id pub-id-type="pmid">25363760</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref014">
<label>14</label>
<mixed-citation publication-type="journal"><name><surname>Iossifov</surname><given-names>I</given-names></name>, <name><surname>Levy</surname><given-names>D</given-names></name>, <name><surname>Allen</surname><given-names>J</given-names></name>, <name><surname>Ye</surname><given-names>K</given-names></name>, <name><surname>Ronemus</surname><given-names>M</given-names></name>, <name><surname>Lee</surname><given-names>YH</given-names></name>, <etal>et al</etal>
<article-title>Low load for disruptive mutations in autism genes and their biased transmission</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America. <year>2015</year>;<volume>112</volume>(<issue>41</issue>):<fpage>E5600</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1516376112</pub-id>
<pub-id pub-id-type="pmid">26401017</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Platzer</surname><given-names>K</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Schutz</surname><given-names>H</given-names></name>, <name><surname>Winschel</surname><given-names>A</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Hu</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects</article-title>. <source/>Journal of medical genetics. <year>2017</year>;<volume>54</volume>(<issue>7</issue>):<fpage>460</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2016-104509</pub-id>
<pub-id pub-id-type="pmid">28377535</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Yoo</surname><given-names>HJ</given-names></name>, <name><surname>Cho</surname><given-names>IH</given-names></name>, <name><surname>Park</surname><given-names>M</given-names></name>, <name><surname>Yang</surname><given-names>SY</given-names></name>, <name><surname>Kim</surname><given-names>SA</given-names></name>. <article-title>Family based association of GRIN2A and GRIN2B with Korean autism spectrum disorders</article-title>. <source/>Neurosci Lett. <year>2012</year>;<volume>512</volume>(<issue>2</issue>):<fpage>89</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2012.01.061</pub-id> .<pub-id pub-id-type="pmid">22326929</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>C</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Myers</surname><given-names>SJ</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name>. <article-title>Human GRIN2B variants in neurodevelopmental disorders</article-title>. <source/>Journal of pharmacological sciences. <year>2016</year>;<volume>132</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jphs.2016.10.002</pub-id>
<pub-id pub-id-type="pmid">27818011</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Burnashev</surname><given-names>N</given-names></name>, <name><surname>Szepetowski</surname><given-names>P</given-names></name>. <article-title>NMDA receptor subunit mutations in neurodevelopmental disorders</article-title>. <source/>Current opinion in pharmacology. <year>2015</year>;<volume>20C</volume>:<fpage>73</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2014.11.008</pub-id> .<pub-id pub-id-type="pmid">25498981</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>Kutsuwada</surname><given-names>T</given-names></name>, <name><surname>Sakimura</surname><given-names>K</given-names></name>, <name><surname>Manabe</surname><given-names>T</given-names></name>, <name><surname>Takayama</surname><given-names>C</given-names></name>, <name><surname>Katakura</surname><given-names>N</given-names></name>, <name><surname>Kushiya</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice</article-title>. <source/>Neuron. <year>1996</year>;<volume>16</volume>(<issue>2</issue>):<fpage>333</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(00)80051-3</pub-id> .<pub-id pub-id-type="pmid">8789948</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Sprengel</surname><given-names>R</given-names></name>, <name><surname>Suchanek</surname><given-names>B</given-names></name>, <name><surname>Amico</surname><given-names>C</given-names></name>, <name><surname>Brusa</surname><given-names>R</given-names></name>, <name><surname>Burnashev</surname><given-names>N</given-names></name>, <name><surname>Rozov</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo</article-title>. <source/>Cell. <year>1998</year>;<volume>92</volume>:<fpage>279</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)80921-6</pub-id>
<pub-id pub-id-type="pmid">9458051</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Brigman</surname><given-names>JL</given-names></name>, <name><surname>Wright</surname><given-names>T</given-names></name>, <name><surname>Talani</surname><given-names>G</given-names></name>, <name><surname>Prasad-Mulcare</surname><given-names>S</given-names></name>, <name><surname>Jinde</surname><given-names>S</given-names></name>, <name><surname>Seabold</surname><given-names>GK</given-names></name>, <etal>et al</etal>
<article-title>Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning</article-title>. <source/>The Journal of neuroscience. <year>2010</year>;<volume>30</volume>(<issue>13</issue>):<fpage>4590</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0640-10.2010</pub-id>
<pub-id pub-id-type="pmid">20357110</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>von Engelhardt</surname><given-names>J</given-names></name>, <name><surname>Doganci</surname><given-names>B</given-names></name>, <name><surname>Jensen</surname><given-names>V</given-names></name>, <name><surname>Hvalby</surname><given-names>O</given-names></name>, <name><surname>Gongrich</surname><given-names>C</given-names></name>, <name><surname>Taylor</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks</article-title>. <source/>Neuron. <year>2008</year>;<volume>60</volume>(<issue>5</issue>):<fpage>846</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.09.039</pub-id> .<pub-id pub-id-type="pmid">19081379</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Akashi</surname><given-names>K</given-names></name>, <name><surname>Kakizaki</surname><given-names>T</given-names></name>, <name><surname>Kamiya</surname><given-names>H</given-names></name>, <name><surname>Fukaya</surname><given-names>M</given-names></name>, <name><surname>Yamasaki</surname><given-names>M</given-names></name>, <name><surname>Abe</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>NMDA receptor GluN2B (GluR epsilon 2/NR2B) subunit is crucial for channel function, postsynaptic macromolecular organization, and actin cytoskeleton at hippocampal CA3 synapses</article-title>. <source/>The Journal of neuroscience. <year>2009</year>;<volume>29</volume>(<issue>35</issue>):<fpage>10869</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5531-08.2009</pub-id> .<pub-id pub-id-type="pmid">19726645</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>Ito</surname><given-names>I</given-names></name>, <name><surname>Futai</surname><given-names>K</given-names></name>, <name><surname>Katagiri</surname><given-names>H</given-names></name>, <name><surname>Watanabe</surname><given-names>M</given-names></name>, <name><surname>Sakimura</surname><given-names>K</given-names></name>, <name><surname>Mishina</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Synapse-selective impairment of NMDA receptor functions in mice lacking NMDA receptor epsilon 1 or epsilon 2 subunit</article-title>. <source/>The Journal of physiology. <year>1997</year>;<volume>500</volume>(<issue>Pt 2</issue>):<fpage>401</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.1997.sp022030</pub-id>
<pub-id pub-id-type="pmid">9147327</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>YP</given-names></name>, <name><surname>Shimizu</surname><given-names>E</given-names></name>, <name><surname>Dube</surname><given-names>GR</given-names></name>, <name><surname>Rampon</surname><given-names>C</given-names></name>, <name><surname>Kerchner</surname><given-names>GA</given-names></name>, <name><surname>Zhuo</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Genetic enhancement of learning and memory in mice</article-title>. <source/>Nature. <year>1999</year>;<volume>401</volume>(<issue>6748</issue>):<fpage>63</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/43432</pub-id> .<pub-id pub-id-type="pmid">10485705</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>XiangWei</surname><given-names>W</given-names></name>, <name><surname>Jiang</surname><given-names>Y</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>. <article-title>De Novo Mutations and Rare Variants Occurring in NMDA Receptors</article-title>. <source/>Curr Opin Physiol. <year>2018</year>;<volume>2</volume>:<fpage>27</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.cophys.2017.12.013</pub-id>
<pub-id pub-id-type="pmid">29756080</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Swanger</surname><given-names>SA</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Wells</surname><given-names>G</given-names></name>, <name><surname>Burger</surname><given-names>PB</given-names></name>, <name><surname>Tankovic</surname><given-names>A</given-names></name>, <name><surname>Bhattacharya</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains</article-title>. <source/>Am J Hum Genet. <year>2016</year>;<volume>99</volume>(<issue>6</issue>):<fpage>1261</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.10.002</pub-id>
<pub-id pub-id-type="pmid">27839871</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Furukawa</surname><given-names>H</given-names></name>, <name><surname>Gouaux</surname><given-names>E</given-names></name>. <article-title>Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core</article-title>. <source/>The EMBO journal. <year>2003</year>;<volume>22</volume>(<issue>12</issue>):<fpage>2873</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/cdg303</pub-id>
<pub-id pub-id-type="pmid">12805203</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref029">
<label>29</label>
<mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>CH</given-names></name>, <name><surname>Lu</surname><given-names>W</given-names></name>, <name><surname>Michel</surname><given-names>JC</given-names></name>, <name><surname>Goehring</surname><given-names>A</given-names></name>, <name><surname>Du</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>NMDA receptor structures reveal subunit arrangement and pore architecture</article-title>. <source/>Nature. <year>2014</year>;<volume>511</volume>(<issue>7508</issue>):<fpage>191</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature13548</pub-id>
<pub-id pub-id-type="pmid">25008524</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Karakas</surname><given-names>E</given-names></name>, <name><surname>Furukawa</surname><given-names>H</given-names></name>. <article-title>Crystal structure of a heterotetrameric NMDA receptor ion channel</article-title>. <source/>Science. <year>2014</year>;<volume>344</volume>(<issue>6187</issue>):<fpage>992</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1251915</pub-id>
<pub-id pub-id-type="pmid">24876489</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref031">
<label>31</label>
<mixed-citation publication-type="journal"><name><surname>Serraz</surname><given-names>B</given-names></name>, <name><surname>Grand</surname><given-names>T</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Altered zinc sensitivity of NMDA receptors harboring clinically-relevant mutations</article-title>. <source/>Neuropharmacology. <year>2016</year>;<volume>109</volume>:<fpage>196</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.06.008</pub-id> .<pub-id pub-id-type="pmid">27288002</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Mony</surname><given-names>L</given-names></name>, <name><surname>Zhu</surname><given-names>S</given-names></name>, <name><surname>Carvalho</surname><given-names>S</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines</article-title>. <source/>The EMBO journal. <year>2011</year>;<volume>30</volume>(<issue>15</issue>):<fpage>3134</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2011.203</pub-id>
<pub-id pub-id-type="pmid">21685875</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><name><surname>Rachline</surname><given-names>J</given-names></name>, <name><surname>Perin-Dureau</surname><given-names>F</given-names></name>, <name><surname>Le Goff</surname><given-names>A</given-names></name>, <name><surname>Neyton</surname><given-names>J</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>The micromolar zinc-binding domain on the NMDA receptor subunit NR2B</article-title>. <source/>The Journal of neuroscience. <year>2005</year>;<volume>25</volume>(<issue>2</issue>):<fpage>308</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3967-04.2005</pub-id> .<pub-id pub-id-type="pmid">15647474</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Sheng</surname><given-names>M</given-names></name>, <name><surname>Cummings</surname><given-names>J</given-names></name>, <name><surname>Roldan</surname><given-names>LA</given-names></name>, <name><surname>Jan</surname><given-names>YN</given-names></name>, <name><surname>Jan</surname><given-names>LY</given-names></name>. <article-title>Changing subunit composition of heteromeric NMDA receptors during development of rat cortex</article-title>. <source/>Nature. <year>1994</year>;<volume>368</volume>(<issue>6467</issue>):<fpage>144</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/368144a0</pub-id> .<pub-id pub-id-type="pmid">8139656</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Stroebel</surname><given-names>D</given-names></name>, <name><surname>Casado</surname><given-names>M</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Triheteromeric NMDA receptors: from structure to synaptic physiology</article-title>. <source/>Curr Opin Physiol. <year>2018</year>;<volume>2</volume>:<fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.cophys.2017.12.004</pub-id>
<pub-id pub-id-type="pmid">29682629</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Tada</surname><given-names>T</given-names></name>, <name><surname>Sheng</surname><given-names>M</given-names></name>. <article-title>Molecular mechanisms of dendritic spine morphogenesis</article-title>. <source/>Current opinion in neurobiology. <year>2006</year>;<volume>16</volume>(<issue>1</issue>):<fpage>95</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2005.12.001</pub-id> .<pub-id pub-id-type="pmid">16361095</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref037">
<label>37</label>
<mixed-citation publication-type="journal"><name><surname>Kennedy</surname><given-names>MB</given-names></name>. <article-title>The postsynaptic density</article-title>. <source/>Current opinion in neurobiology. <year>1993</year>;<volume>3</volume>(<issue>5</issue>):<fpage>732</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0959-4388(93)90145-o</pub-id> .<pub-id pub-id-type="pmid">8260822</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Sheng</surname><given-names>M</given-names></name>, <name><surname>Sala</surname><given-names>C</given-names></name>. <article-title>PDZ domains and the organization of supramolecular complexes</article-title>. <source/>Annual review of neuroscience. <year>2001</year>;<volume>24</volume>:<fpage>1</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.24.1.1</pub-id> .<pub-id pub-id-type="pmid">11283303</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Gray</surname><given-names>JA</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name>, <name><surname>Usui</surname><given-names>H</given-names></name>, <name><surname>During</surname><given-names>MJ</given-names></name>, <name><surname>Sakimura</surname><given-names>K</given-names></name>, <name><surname>Nicoll</surname><given-names>RA</given-names></name>. <article-title>Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo</article-title>. <source/>Neuron. <year>2011</year>;<volume>71</volume>(<issue>6</issue>):<fpage>1085</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.08.007</pub-id>
<pub-id pub-id-type="pmid">21943605</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><name><surname>Bouvier</surname><given-names>G</given-names></name>, <name><surname>Bidoret</surname><given-names>C</given-names></name>, <name><surname>Casado</surname><given-names>M</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Presynaptic NMDA receptors: Roles and rules</article-title>. <source/>Neuroscience. <year>2015</year>;<volume>311</volume>:<fpage>322</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.10.033</pub-id> .<pub-id pub-id-type="pmid">26597763</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Yi</surname><given-names>F</given-names></name>, <name><surname>Danko</surname><given-names>T</given-names></name>, <name><surname>Botelho</surname><given-names>SC</given-names></name>, <name><surname>Patzke</surname><given-names>C</given-names></name>, <name><surname>Pak</surname><given-names>C</given-names></name>, <name><surname>Wernig</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons</article-title>. <source/>Science. <year>2016</year>;<volume>352</volume>(<issue>6286</issue>):<fpage>aaf2669</fpage>
<pub-id pub-id-type="doi">10.1126/science.aaf2669</pub-id>
<pub-id pub-id-type="pmid">26966193</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Silverman</surname><given-names>JL</given-names></name>, <name><surname>Yang</surname><given-names>M</given-names></name>, <name><surname>Lord</surname><given-names>C</given-names></name>, <name><surname>Crawley</surname><given-names>JN</given-names></name>. <article-title>Behavioural phenotyping assays for mouse models of autism</article-title>. <source/>Nature reviews Neuroscience. <year>2010</year>;<volume>11</volume>(<issue>7</issue>):<fpage>490</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2851</pub-id>
<pub-id pub-id-type="pmid">20559336</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>Scattoni</surname><given-names>ML</given-names></name>, <name><surname>Crawley</surname><given-names>J</given-names></name>, <name><surname>Ricceri</surname><given-names>L</given-names></name>. <article-title>Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders</article-title>. <source/>Neuroscience and biobehavioral reviews. <year>2009</year>;<volume>33</volume>(<issue>4</issue>):<fpage>508</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2008.08.003</pub-id>
<pub-id pub-id-type="pmid">18771687</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Willadsen</surname><given-names>M</given-names></name>, <name><surname>Seffer</surname><given-names>D</given-names></name>, <name><surname>Schwarting</surname><given-names>RK</given-names></name>, <name><surname>Wohr</surname><given-names>M</given-names></name>. <article-title>Rodent ultrasonic communication: Male prosocial 50-kHz ultrasonic vocalizations elicit social approach behavior in female rats (Rattus norvegicus)</article-title>. <source/>Journal of comparative psychology. <year>2014</year>;<volume>128</volume>(<issue>1</issue>):<fpage>56</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1037/a0034778</pub-id> .<pub-id pub-id-type="pmid">24188619</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Winslow</surname><given-names>JT</given-names></name>, <name><surname>Insel</surname><given-names>TR</given-names></name>. <article-title>The infant rat separation paradigm: a novel test for novel anxiolytics</article-title>. <source/>Trends Pharmacol Sci. <year>1991</year>;<volume>12</volume>(<issue>11</issue>):<fpage>402</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/0165-6147(91)90616-z</pub-id> .<pub-id pub-id-type="pmid">1686685</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref046">
<label>46</label>
<mixed-citation publication-type="journal"><name><surname>White</surname><given-names>SW</given-names></name>, <name><surname>Oswald</surname><given-names>D</given-names></name>, <name><surname>Ollendick</surname><given-names>T</given-names></name>, <name><surname>Scahill</surname><given-names>L</given-names></name>. <article-title>Anxiety in children and adolescents with autism spectrum disorders</article-title>. <source/>Clin Psychol Rev. <year>2009</year>;<volume>29</volume>(<issue>3</issue>):<fpage>216</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.cpr.2009.01.003</pub-id>
<pub-id pub-id-type="pmid">19223098</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref047">
<label>47</label>
<mixed-citation publication-type="journal"><name><surname>Schade</surname><given-names>S</given-names></name>, <name><surname>Paulus</surname><given-names>W</given-names></name>. <article-title>D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review</article-title>. <source/>The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. <year>2016</year>;<volume>19</volume>(<issue>4</issue>). <pub-id pub-id-type="doi">10.1093/ijnp/pyv102</pub-id>
<pub-id pub-id-type="pmid">26364274</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref048">
<label>48</label>
<mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>EJ</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>TN</given-names></name>, <name><surname>Chung</surname><given-names>C</given-names></name>, <name><surname>Shin</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Trans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activation</article-title>. <source/>Nat Commun. <year>2015</year>;<volume>6</volume>:<fpage>7168</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms8168</pub-id>
<pub-id pub-id-type="pmid">25981743</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref049">
<label>49</label>
<mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>TN</given-names></name>, <name><surname>Chuang</surname><given-names>HC</given-names></name>, <name><surname>Chou</surname><given-names>WH</given-names></name>, <name><surname>Chen</surname><given-names>CY</given-names></name>, <name><surname>Wang</surname><given-names>HF</given-names></name>, <name><surname>Chou</surname><given-names>SJ</given-names></name>, <etal>et al</etal>
<article-title>Tbr1 haploinsufficiency impairs amygdalar axonal projections and results in cognitive abnormality</article-title>. <source/>Nat Neurosci. <year>2014</year>;<volume>17</volume>(<issue>2</issue>):<fpage>240</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3626</pub-id> .<pub-id pub-id-type="pmid">24441682</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref050">
<label>50</label>
<mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>TN</given-names></name>, <name><surname>Yen</surname><given-names>TL</given-names></name>, <name><surname>Qiu</surname><given-names>LR</given-names></name>, <name><surname>Chuang</surname><given-names>HC</given-names></name>, <name><surname>Lerch</surname><given-names>JP</given-names></name>, <name><surname>Hsueh</surname><given-names>YP</given-names></name>. <article-title>Haploinsufficiency of autism causative gene Tbr1 impairs olfactory discrimination and neuronal activation of the olfactory system in mice</article-title>. <source/>Molecular autism. <year>2019</year>;<volume>10</volume>:<fpage>5</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-019-0257-5</pub-id>
<pub-id pub-id-type="pmid">30792833</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref051">
<label>51</label>
<mixed-citation publication-type="journal"><name><surname>Mabb</surname><given-names>AM</given-names></name>, <name><surname>Ehlers</surname><given-names>MD</given-names></name>. <article-title>Ubiquitination in postsynaptic function and plasticity</article-title>. <source/>Annual review of cell and developmental biology. <year>2010</year>;<volume>26</volume>:<fpage>179</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100109-104129</pub-id>
<pub-id pub-id-type="pmid">20604708</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref052">
<label>52</label>
<mixed-citation publication-type="journal"><name><surname>Tai</surname><given-names>HC</given-names></name>, <name><surname>Schuman</surname><given-names>EM</given-names></name>. <article-title>Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction</article-title>. <source/>Nature reviews Neuroscience. <year>2008</year>;<volume>9</volume>(<issue>11</issue>):<fpage>826</fpage>–<lpage>38</lpage>. nrn2499 [pii] <pub-id pub-id-type="doi">10.1038/nrn2499</pub-id> .<pub-id pub-id-type="pmid">18931696</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref053">
<label>53</label>
<mixed-citation publication-type="journal"><name><surname>Kawabe</surname><given-names>H</given-names></name>, <name><surname>Brose</surname><given-names>N</given-names></name>. <article-title>The role of ubiquitylation in nerve cell development</article-title>. <source/>Nature reviews Neuroscience. <year>2011</year>;<volume>12</volume>(<issue>5</issue>):<fpage>251</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3009</pub-id> .<pub-id pub-id-type="pmid">21505515</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref054">
<label>54</label>
<mixed-citation publication-type="journal"><name><surname>Yi</surname><given-names>JJ</given-names></name>, <name><surname>Ehlers</surname><given-names>MD</given-names></name>. <article-title>Emerging roles for ubiquitin and protein degradation in neuronal function</article-title>. <source/>Pharmacological reviews. <year>2007</year>;<volume>59</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1124/pr.59.1.4</pub-id> .<pub-id pub-id-type="pmid">17329546</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref055">
<label>55</label>
<mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>DB</given-names></name>, <name><surname>Michailidis</surname><given-names>I</given-names></name>, <name><surname>Mu</surname><given-names>Y</given-names></name>, <name><surname>Logothetis</surname><given-names>D</given-names></name>, <name><surname>Ehlers</surname><given-names>MD</given-names></name>. <article-title>Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals</article-title>. <source/>The Journal of neuroscience. <year>2004</year>;<volume>24</volume>(<issue>32</issue>):<fpage>7096</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0780-04.2004</pub-id> .<pub-id pub-id-type="pmid">15306643</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref056">
<label>56</label>
<mixed-citation publication-type="journal"><name><surname>Kennedy</surname><given-names>MJ</given-names></name>, <name><surname>Ehlers</surname><given-names>MD</given-names></name>. <article-title>Organelles and trafficking machinery for postsynaptic plasticity</article-title>. <source/>Annual review of neuroscience. <year>2006</year>;<volume>29</volume>:<fpage>325</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.29.051605.112808</pub-id> .<pub-id pub-id-type="pmid">16776589</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref057">
<label>57</label>
<mixed-citation publication-type="journal"><name><surname>Chazot</surname><given-names>PL</given-names></name>, <name><surname>Stephenson</surname><given-names>FA</given-names></name>. <article-title>Molecular dissection of native mammalian forebrain NMDA receptors containing the NR1 C2 exon: direct demonstration of NMDA receptors comprising NR1, NR2A, and NR2B subunits within the same complex</article-title>. <source/>Journal of neurochemistry. <year>1997</year>;<volume>69</volume>(<issue>5</issue>):<fpage>2138</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.1997.69052138.x</pub-id> .<pub-id pub-id-type="pmid">9349560</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref058">
<label>58</label>
<mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Yasuda</surname><given-names>RP</given-names></name>, <name><surname>Dunah</surname><given-names>AW</given-names></name>, <name><surname>Wolfe</surname><given-names>BB</given-names></name>. <article-title>The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B)</article-title>. <source/>Molecular pharmacology. <year>1997</year>;<volume>51</volume>(<issue>1</issue>):<fpage>79</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1124/mol.51.1.79</pub-id> .<pub-id pub-id-type="pmid">9016349</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref059">
<label>59</label>
<mixed-citation publication-type="journal"><name><surname>Rauner</surname><given-names>C</given-names></name>, <name><surname>Kohr</surname><given-names>G</given-names></name>. <article-title>Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses</article-title>. <source/>The Journal of biological chemistry. <year>2011</year>;<volume>286</volume>(<issue>9</issue>):<fpage>7558</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.182600</pub-id>
<pub-id pub-id-type="pmid">21190942</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref060">
<label>60</label>
<mixed-citation publication-type="journal"><name><surname>Tovar</surname><given-names>KR</given-names></name>, <name><surname>McGinley</surname><given-names>MJ</given-names></name>, <name><surname>Westbrook</surname><given-names>GL</given-names></name>. <article-title>Triheteromeric NMDA receptors at hippocampal synapses</article-title>. <source/>The Journal of neuroscience. <year>2013</year>;<volume>33</volume>(<issue>21</issue>):<fpage>9150</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0829-13.2013</pub-id>
<pub-id pub-id-type="pmid">23699525</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref061">
<label>61</label>
<mixed-citation publication-type="journal"><name><surname>Hatton</surname><given-names>CJ</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Modulation of triheteromeric NMDA receptors by N-terminal domain ligands</article-title>. <source/>Neuron. <year>2005</year>;<volume>46</volume>(<issue>2</issue>):<fpage>261</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2005.03.005</pub-id> .<pub-id pub-id-type="pmid">15848804</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref062">
<label>62</label>
<mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>KB</given-names></name>, <name><surname>Ogden</surname><given-names>KK</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name>. <article-title>Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors</article-title>. <source/>Neuron. <year>2014</year>;<volume>81</volume>(<issue>5</issue>):<fpage>1084</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.01.035</pub-id>
<pub-id pub-id-type="pmid">24607230</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref063">
<label>63</label>
<mixed-citation publication-type="journal"><name><surname>Stroebel</surname><given-names>D</given-names></name>, <name><surname>Carvalho</surname><given-names>S</given-names></name>, <name><surname>Grand</surname><given-names>T</given-names></name>, <name><surname>Zhu</surname><given-names>S</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Controlling NMDA receptor subunit composition using ectopic retention signals</article-title>. <source/>The Journal of neuroscience: the official journal of the Society for Neuroscience. <year>2014</year>;<volume>34</volume>(<issue>50</issue>):<fpage>16630</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2736-14.2014</pub-id> .<pub-id pub-id-type="pmid">25505316</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref064">
<label>64</label>
<mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Wong</surname><given-names>TP</given-names></name>, <name><surname>Pozza</surname><given-names>MF</given-names></name>, <name><surname>Lingenhoehl</surname><given-names>K</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Sheng</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity</article-title>. <source/>Science. <year>2004</year>;<volume>304</volume>(<issue>5673</issue>):<fpage>1021</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.1096615</pub-id> .<pub-id pub-id-type="pmid">15143284</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref065">
<label>65</label>
<mixed-citation publication-type="journal"><name><surname>Massey</surname><given-names>PV</given-names></name>, <name><surname>Johnson</surname><given-names>BE</given-names></name>, <name><surname>Moult</surname><given-names>PR</given-names></name>, <name><surname>Auberson</surname><given-names>YP</given-names></name>, <name><surname>Brown</surname><given-names>MW</given-names></name>, <name><surname>Molnar</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression</article-title>. <source/>The Journal of neuroscience. <year>2004</year>;<volume>24</volume>(<issue>36</issue>):<fpage>7821</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1697-04.2004</pub-id> .<pub-id pub-id-type="pmid">15356193</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref066">
<label>66</label>
<mixed-citation publication-type="journal"><name><surname>Fox</surname><given-names>CJ</given-names></name>, <name><surname>Russell</surname><given-names>KI</given-names></name>, <name><surname>Wang</surname><given-names>YT</given-names></name>, <name><surname>Christie</surname><given-names>BR</given-names></name>. <article-title>Contribution of NR2A and NR2B NMDA subunits to bidirectional synaptic plasticity in the hippocampus in vivo</article-title>. <source/>Hippocampus. <year>2006</year>;<volume>16</volume>(<issue>11</issue>):<fpage>907</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.20230</pub-id> .<pub-id pub-id-type="pmid">17024679</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref067">
<label>67</label>
<mixed-citation publication-type="journal"><name><surname>Izumi</surname><given-names>Y</given-names></name>, <name><surname>Auberson</surname><given-names>YP</given-names></name>, <name><surname>Zorumski</surname><given-names>CF</given-names></name>. <article-title>Zinc modulates bidirectional hippocampal plasticity by effects on NMDA receptors</article-title>. <source/>The Journal of neuroscience. <year>2006</year>;<volume>26</volume>(<issue>27</issue>):<fpage>7181</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1258-06.2006</pub-id> .<pub-id pub-id-type="pmid">16822975</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref068">
<label>68</label>
<mixed-citation publication-type="journal"><name><surname>Bartlett</surname><given-names>TE</given-names></name>, <name><surname>Bannister</surname><given-names>NJ</given-names></name>, <name><surname>Collett</surname><given-names>VJ</given-names></name>, <name><surname>Dargan</surname><given-names>SL</given-names></name>, <name><surname>Massey</surname><given-names>PV</given-names></name>, <name><surname>Bortolotto</surname><given-names>ZA</given-names></name>, <etal>et al</etal>
<article-title>Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus</article-title>. <source/>Neuropharmacology. <year>2007</year>;<volume>52</volume>(<issue>1</issue>):<fpage>60</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2006.07.013</pub-id> .<pub-id pub-id-type="pmid">16904707</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref069">
<label>69</label>
<mixed-citation publication-type="journal"><name><surname>Morishita</surname><given-names>W</given-names></name>, <name><surname>Lu</surname><given-names>W</given-names></name>, <name><surname>Smith</surname><given-names>GB</given-names></name>, <name><surname>Nicoll</surname><given-names>RA</given-names></name>, <name><surname>Bear</surname><given-names>MF</given-names></name>, <name><surname>Malenka</surname><given-names>RC</given-names></name>. <article-title>Activation of NR2B-containing NMDA receptors is not required for NMDA receptor-dependent long-term depression</article-title>. <source/>Neuropharmacology. <year>2007</year>;<volume>52</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2006.07.005</pub-id> .<pub-id pub-id-type="pmid">16899258</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref070">
<label>70</label>
<mixed-citation publication-type="journal"><name><surname>Shipton</surname><given-names>OA</given-names></name>, <name><surname>Paulsen</surname><given-names>O</given-names></name>. <article-title>GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity</article-title>. <source/>Philosophical transactions of the Royal Society of London Series B, Biological sciences. <year>2014</year>;<volume>369</volume>(<issue>1633</issue>):<fpage>20130163</fpage>
<pub-id pub-id-type="doi">10.1098/rstb.2013.0163</pub-id>
<pub-id pub-id-type="pmid">24298164</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref071">
<label>71</label>
<mixed-citation publication-type="journal"><name><surname>Neyton</surname><given-names>J</given-names></name>, <name><surname>Paoletti</surname><given-names>P</given-names></name>. <article-title>Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach</article-title>. <source/>The Journal of neuroscience. <year>2006</year>;<volume>26</volume>(<issue>5</issue>):<fpage>1331</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5242-05.2006</pub-id> .<pub-id pub-id-type="pmid">16452656</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref072">
<label>72</label>
<mixed-citation publication-type="journal"><name><surname>Tovar</surname><given-names>KR</given-names></name>, <name><surname>Westbrook</surname><given-names>GL</given-names></name>. <article-title>Amino-terminal ligands prolong NMDA Receptor-mediated EPSCs</article-title>. <source/>The Journal of neuroscience. <year>2012</year>;<volume>32</volume>(<issue>23</issue>):<fpage>8065</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0538-12.2012</pub-id>
<pub-id pub-id-type="pmid">22674281</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref073">
<label>73</label>
<mixed-citation publication-type="journal"><name><surname>Kew</surname><given-names>JN</given-names></name>, <name><surname>Trube</surname><given-names>G</given-names></name>, <name><surname>Kemp</surname><given-names>JA</given-names></name>. <article-title>A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones</article-title>. <source/>The Journal of physiology. <year>1996</year>;<volume>497</volume>(<issue>Pt 3</issue>):<fpage>761</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.1996.sp021807</pub-id>
<pub-id pub-id-type="pmid">9003561</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref074">
<label>74</label>
<mixed-citation publication-type="journal"><name><surname>Dore</surname><given-names>K</given-names></name>, <name><surname>Aow</surname><given-names>J</given-names></name>, <name><surname>Malinow</surname><given-names>R</given-names></name>. <article-title>Agonist binding to the NMDA receptor drives movement of its cytoplasmic domain without ion flow</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America. <year>2015</year>;<volume>112</volume>(<issue>47</issue>):<fpage>14705</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1520023112</pub-id>
<pub-id pub-id-type="pmid">26553997</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref075">
<label>75</label>
<mixed-citation publication-type="journal"><name><surname>Nabavi</surname><given-names>S</given-names></name>, <name><surname>Kessels</surname><given-names>HW</given-names></name>, <name><surname>Alfonso</surname><given-names>S</given-names></name>, <name><surname>Aow</surname><given-names>J</given-names></name>, <name><surname>Fox</surname><given-names>R</given-names></name>, <name><surname>Malinow</surname><given-names>R</given-names></name>. <article-title>Metabotropic NMDA receptor function is required for NMDA receptor-dependent long-term depression</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America. <year>2013</year>;<volume>110</volume>(<issue>10</issue>):<fpage>4027</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1219454110</pub-id>
<pub-id pub-id-type="pmid">23431133</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref076">
<label>76</label>
<mixed-citation publication-type="journal"><name><surname>Stein</surname><given-names>IS</given-names></name>, <name><surname>Gray</surname><given-names>JA</given-names></name>, <name><surname>Zito</surname><given-names>K</given-names></name>. <article-title>Non-Ionotropic NMDA Receptor Signaling Drives Activity-Induced Dendritic Spine Shrinkage</article-title>. <source/>The Journal of neuroscience. <year>2015</year>;<volume>35</volume>(<issue>35</issue>):<fpage>12303</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4289-14.2015</pub-id>
<pub-id pub-id-type="pmid">26338340</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref077">
<label>77</label>
<mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>JM</given-names></name>, <name><surname>Gray</surname><given-names>JA</given-names></name>. <article-title>Long-Term Depression Is Independent of GluN2 Subunit Composition</article-title>. <source/>The Journal of neuroscience: the official journal of the Society for Neuroscience. <year>2018</year>;<volume>38</volume>(<issue>19</issue>):<fpage>4462</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0394-18.2018</pub-id>
<pub-id pub-id-type="pmid">29593052</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref078">
<label>78</label>
<mixed-citation publication-type="journal"><name><surname>Gillott</surname><given-names>A</given-names></name>, <name><surname>Furniss</surname><given-names>F</given-names></name>, <name><surname>Walter</surname><given-names>A</given-names></name>. <article-title>Anxiety in high-functioning children with autism</article-title>. <source/>Autism. <year>2001</year>;<volume>5</volume>(<issue>3</issue>):<fpage>277</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1177/1362361301005003005</pub-id> .<pub-id pub-id-type="pmid">11708587</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref079">
<label>79</label>
<mixed-citation publication-type="journal"><name><surname>Ey</surname><given-names>E</given-names></name>, <name><surname>Leblond</surname><given-names>CS</given-names></name>, <name><surname>Bourgeron</surname><given-names>T</given-names></name>. <article-title>Behavioral profiles of mouse models for autism spectrum disorders</article-title>. <source/>Autism research. <year>2011</year>;<volume>4</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1002/aur.175</pub-id> .<pub-id pub-id-type="pmid">21328568</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref080">
<label>80</label>
<mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>YH</given-names></name>, <name><surname>Ehlers</surname><given-names>MD</given-names></name>. <article-title>Modeling autism by SHANK gene mutations in mice</article-title>. <source/>Neuron. <year>2013</year>;<volume>78</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.03.016</pub-id>
<pub-id pub-id-type="pmid">23583105</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref081">
<label>81</label>
<mixed-citation publication-type="journal"><name><surname>Winslow</surname><given-names>JT</given-names></name>, <name><surname>Hearn</surname><given-names>EF</given-names></name>, <name><surname>Ferguson</surname><given-names>J</given-names></name>, <name><surname>Young</surname><given-names>LJ</given-names></name>, <name><surname>Matzuk</surname><given-names>MM</given-names></name>, <name><surname>Insel</surname><given-names>TR</given-names></name>. <article-title>Infant vocalization, adult aggression, and fear behavior of an oxytocin null mutant mouse</article-title>. <source/>Hormones and behavior. <year>2000</year>;<volume>37</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1006/hbeh.1999.1566</pub-id> .<pub-id pub-id-type="pmid">10753584</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref082">
<label>82</label>
<mixed-citation publication-type="journal"><name><surname>Guastella</surname><given-names>AJ</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name>. <article-title>Oxytocin Treatment, Circuitry, and Autism: A Critical Review of the Literature Placing Oxytocin Into the Autism Context</article-title>. <source/>Biological psychiatry. <year>2016</year>;<volume>79</volume>(<issue>3</issue>):<fpage>234</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.06.028</pub-id> .<pub-id pub-id-type="pmid">26257243</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref083">
<label>83</label>
<mixed-citation publication-type="journal"><name><surname>Malenka</surname><given-names>RC</given-names></name>, <name><surname>Bear</surname><given-names>MF</given-names></name>. <article-title>LTP and LTD: an embarrassment of riches</article-title>. <source/>Neuron. <year>2004</year>;<volume>44</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2004.09.012</pub-id> .<pub-id pub-id-type="pmid">15450156</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref084">
<label>84</label>
<mixed-citation publication-type="journal"><name><surname>Collingridge</surname><given-names>GL</given-names></name>, <name><surname>Peineau</surname><given-names>S</given-names></name>, <name><surname>Howland</surname><given-names>JG</given-names></name>, <name><surname>Wang</surname><given-names>YT</given-names></name>. <article-title>Long-term depression in the CNS</article-title>. <source/>Nature reviews Neuroscience. <year>2010</year>;<volume>11</volume>(<issue>7</issue>):<fpage>459</fpage>–<lpage>73</lpage>. nrn2867 [pii] <pub-id pub-id-type="doi">10.1038/nrn2867</pub-id> .<pub-id pub-id-type="pmid">20559335</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref085">
<label>85</label>
<mixed-citation publication-type="journal"><name><surname>Ritter</surname><given-names>LM</given-names></name>, <name><surname>Vazquez</surname><given-names>DM</given-names></name>, <name><surname>Meador-Woodruff</surname><given-names>JH</given-names></name>. <article-title>Ontogeny of ionotropic glutamate receptor subunit expression in the rat hippocampus</article-title>. <source/>Brain research Developmental brain research. <year>2002</year>;<volume>139</volume>(<issue>2</issue>):<fpage>227</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-3806(02)00572-2</pub-id> .<pub-id pub-id-type="pmid">12480137</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref086">
<label>86</label>
<mixed-citation publication-type="journal"><name><surname>Kemp</surname><given-names>N</given-names></name>, <name><surname>McQueen</surname><given-names>J</given-names></name>, <name><surname>Faulkes</surname><given-names>S</given-names></name>, <name><surname>Bashir</surname><given-names>ZI</given-names></name>. <article-title>Different forms of LTD in the CA1 region of the hippocampus: role of age and stimulus protocol</article-title>. <source/>The European journal of neuroscience. <year>2000</year>;<volume>12</volume>(<issue>1</issue>):<fpage>360</fpage>–<lpage>6</lpage>. ejn903 [pii]. <pub-id pub-id-type="doi">10.1046/j.1460-9568.2000.00903.x</pub-id> .<pub-id pub-id-type="pmid">10651891</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref087">
<label>87</label>
<mixed-citation publication-type="journal"><name><surname>Errington</surname><given-names>ML</given-names></name>, <name><surname>Bliss</surname><given-names>TV</given-names></name>, <name><surname>Richter-Levin</surname><given-names>G</given-names></name>, <name><surname>Yenk</surname><given-names>K</given-names></name>, <name><surname>Doyere</surname><given-names>V</given-names></name>, <name><surname>Laroche</surname><given-names>S</given-names></name>. <article-title>Stimulation at 1–5 Hz does not produce long-term depression or depotentiation in the hippocampus of the adult rat in vivo</article-title>. <source/>Journal of neurophysiology. <year>1995</year>;<volume>74</volume>(<issue>4</issue>):<fpage>1793</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1152/jn.1995.74.4.1793</pub-id> .<pub-id pub-id-type="pmid">8989415</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref088">
<label>88</label>
<mixed-citation publication-type="journal"><name><surname>Nakai</surname><given-names>N</given-names></name>, <name><surname>Nagano</surname><given-names>M</given-names></name>, <name><surname>Saitow</surname><given-names>F</given-names></name>, <name><surname>Watanabe</surname><given-names>Y</given-names></name>, <name><surname>Kawamura</surname><given-names>Y</given-names></name>, <name><surname>Kawamoto</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Serotonin rebalances cortical tuning and behavior linked to autism symptoms in 15q11-13 CNV mice</article-title>. <source/>Sci Adv. <year>2017</year>;<volume>3</volume>(<issue>6</issue>):<fpage>e1603001</fpage>
<pub-id pub-id-type="doi">10.1126/sciadv.1603001</pub-id>
<pub-id pub-id-type="pmid">28691086</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref089">
<label>89</label>
<mixed-citation publication-type="journal"><name><surname>Chung</surname><given-names>C</given-names></name>, <name><surname>Ha</surname><given-names>S</given-names></name>, <name><surname>Kang</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Um</surname><given-names>SM</given-names></name>, <name><surname>Yan</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Early Correction of N-Methyl-D-Aspartate Receptor Function Improves Autistic-like Social Behaviors in Adult Shank2(-/-) Mice</article-title>. <source/>Biological psychiatry. <year>2019</year>;<volume>85</volume>(<issue>7</issue>):<fpage>534</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2018.09.025</pub-id>
<pub-id pub-id-type="pmid">30466882</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref090">
<label>90</label>
<mixed-citation publication-type="journal"><name><surname>Tovote</surname><given-names>P</given-names></name>, <name><surname>Fadok</surname><given-names>JP</given-names></name>, <name><surname>Luthi</surname><given-names>A</given-names></name>. <article-title>Neuronal circuits for fear and anxiety</article-title>. <source/>Nat Rev Neurosci. <year>2015</year>;<volume>16</volume>(<issue>6</issue>):<fpage>317</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3945</pub-id> .<pub-id pub-id-type="pmid">25991441</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref091">
<label>91</label>
<mixed-citation publication-type="journal"><name><surname>Apps</surname><given-names>R</given-names></name>, <name><surname>Strata</surname><given-names>P</given-names></name>. <article-title>Neuronal circuits for fear and anxiety—the missing link</article-title>. <source/>Nat Rev Neurosci. <year>2015</year>;<volume>16</volume>(<issue>10</issue>):<fpage>642</fpage>
<pub-id pub-id-type="doi">10.1038/nrn4028</pub-id> .<pub-id pub-id-type="pmid">26333516</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref092">
<label>92</label>
<mixed-citation publication-type="journal"><name><surname>Calhoon</surname><given-names>GG</given-names></name>, <name><surname>Tye</surname><given-names>KM</given-names></name>. <article-title>Resolving the neural circuits of anxiety</article-title>. <source/>Nat Neurosci. <year>2015</year>;<volume>18</volume>(<issue>10</issue>):<fpage>1394</fpage>–<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4101</pub-id> .<pub-id pub-id-type="pmid">26404714</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref093">
<label>93</label>
<mixed-citation publication-type="journal"><name><surname>Adhikari</surname><given-names>A.</given-names></name>
<article-title>Distributed circuits underlying anxiety</article-title>. <source/>Front Behav Neurosci. <year>2014</year>;<volume>8</volume>:<fpage>112</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2014.00112</pub-id>
<pub-id pub-id-type="pmid">24744710</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref094">
<label>94</label>
<mixed-citation publication-type="journal"><name><surname>Duval</surname><given-names>ER</given-names></name>, <name><surname>Javanbakht</surname><given-names>A</given-names></name>, <name><surname>Liberzon</surname><given-names>I</given-names></name>. <article-title>Neural circuits in anxiety and stress disorders: a focused review</article-title>. <source/>Ther Clin Risk Manag. <year>2015</year>;<volume>11</volume>:<fpage>115</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S48528</pub-id>
<pub-id pub-id-type="pmid">25670901</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref095">
<label>95</label>
<mixed-citation publication-type="journal"><name><surname>Duvarci</surname><given-names>S</given-names></name>, <name><surname>Bauer</surname><given-names>EP</given-names></name>, <name><surname>Paré</surname><given-names>DJJoN</given-names></name>. <article-title>The bed nucleus of the stria terminalis mediates inter-individual variations in anxiety and fear</article-title>. <year>2009</year>;<volume>29</volume>(<issue>33</issue>):<fpage>10357</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2119-09.2009</pub-id>
<pub-id pub-id-type="pmid">19692610</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref096">
<label>96</label>
<mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Adhikari</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>SY</given-names></name>, <name><surname>Marshel</surname><given-names>JH</given-names></name>, <name><surname>Kim</surname><given-names>CK</given-names></name>, <name><surname>Mallory</surname><given-names>CS</given-names></name>, <etal>et al</etal>
<article-title>Diverging neural pathways assemble a behavioural state from separable features in anxiety</article-title>. <source/>Nature. <year>2013</year>;<volume>496</volume>(<issue>7444</issue>):<fpage>219</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/nature12018</pub-id> .<pub-id pub-id-type="pmid">23515158</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref097">
<label>97</label>
<mixed-citation publication-type="journal"><name><surname>Avery</surname><given-names>SN</given-names></name>, <name><surname>Clauss</surname><given-names>JA</given-names></name>, <name><surname>Blackford</surname><given-names>JU</given-names></name>. <article-title>The Human BNST: Functional Role in Anxiety and Addiction</article-title>. <source/>Neuropsychopharmacology. <year>2016</year>;<volume>41</volume>(<issue>1</issue>):<fpage>126</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.185</pub-id>
<pub-id pub-id-type="pmid">26105138</pub-id></mixed-citation>
</ref>
<ref id="pbio.3000717.ref098">
<label>98</label>
<mixed-citation publication-type="journal"><name><surname>Barkus</surname><given-names>C</given-names></name>, <name><surname>McHugh</surname><given-names>SB</given-names></name>, <name><surname>Sprengel</surname><given-names>R</given-names></name>, <name><surname>Seeburg</surname><given-names>PH</given-names></name>, <name><surname>Rawlins</surname><given-names>JN</given-names></name>, <name><surname>Bannerman</surname><given-names>DM</given-names></name>. <article-title>Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion</article-title>. <source/>European journal of pharmacology. <year>2010</year>;<volume>626</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2009.10.014</pub-id>
<pub-id pub-id-type="pmid">19836379</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
<sub-article article-type="author-comment" id="pbio.3000717.r001">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717.r001</article-id>
<title-group>
<article-title>Author response to previous submission</article-title>
</title-group>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">24 Feb 2020</named-content>
</p>
<supplementary-material content-type="local-data" id="pbio.3000717.s017">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Point by point responses to referee comments.docx</named-content></p>
</caption>
<media xlink:href="pbio.3000717.s017.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pbio.3000717.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717.r002</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gasque</surname>
<given-names>Gabriel</given-names>
</name>
<role>Senior Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-statement>© 2020 Gabriel Gasque</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Gabriel Gasque</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-article ext-link-type="doi" id="rel-obj002" related-article-type="reviewed-article" xlink:href="10.1371/journal.pbio.3000717"></related-article>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">27 Feb 2020</named-content>
</p>
<p>Dear Eunjoon, </p>
<p>Thank you for submitting your revised manuscript entitled "Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice" for consideration as a Research Article by PLOS Biology.</p>
<p>Your revision has now been evaluated by the PLOS Biology editorial staff, as well as by the original Academic Editor, and I am writing to let you know that we would like to send your submission out for external peer review.</p>
<p>However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.</p>
<p>Please re-submit your manuscript within two working days, i.e. by Mar 02 2020 11:59PM.</p>
<p>Login to Editorial Manager here: <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pbiology">https://www.editorialmanager.com/pbiology</ext-link>
</p>
<p>During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosbiology/s/preprints">http://journals.plos.org/plosbiology/s/preprints</ext-link> for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit. </p>
<p>Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review. </p>
<p>Feel free to email us at <email>plosbiology@plos.org</email> if you have any queries relating to your submission.</p>
<p>Kind regards,</p>
<p>Gabriel Gasque, Ph.D.,</p>
<p>Senior Editor</p>
<p>PLOS Biology</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pbio.3000717.r003">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717.r003</article-id>
<title-group>
<article-title>Author response to Decision Letter 0</article-title>
</title-group>
<related-article ext-link-type="doi" id="rel-obj003" related-article-type="editor-report" xlink:href="10.1371/journal.pbio.3000717"></related-article>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">28 Feb 2020</named-content>
</p>
<supplementary-material content-type="local-data" id="pbio.3000717.s018">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Point by point responses to referee comments.docx</named-content></p>
</caption>
<media xlink:href="pbio.3000717.s018.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pbio.3000717.r004">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717.r004</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gasque</surname>
<given-names>Gabriel</given-names>
</name>
<role>Senior Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-statement>© 2020 Gabriel Gasque</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Gabriel Gasque</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-article ext-link-type="doi" id="rel-obj004" related-article-type="reviewed-article" xlink:href="10.1371/journal.pbio.3000717"></related-article>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">26 Mar 2020</named-content>
</p>
<p>Dear Eunjoon,</p>
<p>Thank you for submitting your revised Research Article entitled "Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice" for publication in PLOS Biology. I have now obtained advice from the original reviewers and have discussed their comments with the Academic Editor. </p>
<p>Based on the reviews, we will probably accept this manuscript for publication, assuming that you will modify the manuscript to address the remaining points raised by reviewer 2. Please also make sure to address the data and other policy-related requests noted at the end of this email.</p>
<p>We expect to receive your revised manuscript within two weeks. Your revisions should address the specific points made by reviewer 2. Please submit the following files along with your revised manuscript:</p>
<p>1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript. </p>
<p>*NOTE: In your point by point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point.</p>
<p>2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Related" file type.</p>
<p>In addition to the remaining revisions and before we will be able to formally accept your manuscript and consider it "in press", we also need to ensure that your article conforms to our guidelines. A member of our team will be in touch shortly with a set of requests. As we can't proceed until these requirements are met, your swift response will help prevent delays to publication.</p>
<p>*Copyediting*</p>
<p>Upon acceptance of your article, your final files will be copyedited and typeset into the final PDF. While you will have an opportunity to review these files as proofs, PLOS will only permit corrections to spelling or significant scientific errors. Therefore, please take this final revision time to assess and make any remaining major changes to your manuscript.</p>
<p>NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosbiology/s/supporting-information">https://journals.plos.org/plosbiology/s/supporting-information</ext-link>
</p>
<p>*Published Peer Review History*</p>
<p>Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/">https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/</ext-link>
</p>
<p>*Early Version*</p>
<p>Please note that an uncorrected proof of your manuscript will be published online ahead of the final version, unless you opted out when submitting your manuscript. If, for any reason, you do not want an earlier version of your manuscript published online, uncheck the box. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.</p>
<p>*Protocols deposition*</p>
<p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods">https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods</ext-link>
</p>
<p>*Submitting Your Revision*</p>
<p>To submit your revision, please go to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pbiology/">https://www.editorialmanager.com/pbiology/</ext-link> and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include a cover letter, a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable), and a track-changes file indicating any changes that you have made to the manuscript. </p>
<p>Please do not hesitate to contact me should you have any questions.</p>
<p>Sincerely,</p>
<p>Gabriel Gasque, Ph.D., </p>
<p>Senior Editor</p>
<p>PLOS Biology</p>
<p>------------------------------------------------------------------------</p>
<p>DATA POLICY:</p>
<p>--Please update your S3 Data file to include Figure S2C.</p>
<p>-- Please also ensure that figure legends in your manuscript include information on where the underlying data can be found, and ensure your supplemental data file/s has a legend.</p>
<p> ------------------------------------------------------------------------</p>
<p>BLOT AND GEL REPORTING REQUIREMENTS:</p>
<p>For manuscripts submitted on or after 1st July 2019, we require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare and upload them now. Please carefully read our guidelines for how to prepare and upload this data: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements">https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements</ext-link>
</p>
<p>------------------------------------------------------------------------</p>
<p>Reviewer remarks:</p>
<p>Reviewer #1: The authors have adequately addressed the majority of this reviewer's concerns. With the significant changes made to the manuscript during the revision, the paper is suitable for publication.</p>
<p>Reviewer #2, Marc Fuccillo: The authors have attempted to address many of my requests. In doing so, they have strengthened the idea that the C456Y point mutant functions like the NR2B heterozygous LOF mutation, both at the synaptic, protein and behavioral level. While perhaps expected, these data provide clarity to the role of ASD-associated NMDAR mutations. Another strong plus is the addition of data showing a similar plasticity effect in the mPFC. these data suggest that the data in hippo are a proxy for other areas (something that should be mentioned in the text). </p>
<p>Overall, I feel like this is a strong contribution to the asd pathophysiology literature. while not incredibly surprising, the data is clear and makes a strong point supporting this specific disease-associated mutation as GRIN2B haploinsufficiency. the reproducibility of DCS rescue across assays is also a strength. </p>
<p>A few short textual things should be added:</p>
<p>1. discuss the relationship between anxiogenic and anxiolytic behaviors as they relate to ASD. these are not part of the core behavioral phenotype but are the most clearly altered in this work. the literature on ASD and anxiety-related behaviors should be discussed.</p>
<p>2. please discuss that in light of the mPFC data, it is unclear which brain regions are contributing to the mutation-associated behavioral (and rescue-related) changes.</p>
<p>3. "suppressed recognition of the fact that a dark and closed place is generally safe" - this isn't any better than before - perhaps just describe the phenotype.</p>
<p>Reviewer #3: The authors performed extra experiments and gave explanations to address all the questions raised by the reviewers. The manuscript became even more data heavy and the conclusions are now better discussed to support the authors ideas. Although there are some technical issues, the authors do demonstrate GluN2B-C456Y haploinsufficiency decreases GluN2B protein levels, LTD, and anxiety-like behavior. The overall behavioral and physiological experiments provide an insight for the importance of early correction of pathophysiological deficits.</p>
<p>The findings are important in the field for the treatment of neurodevelopmental or psychiatric diseases caused by NMDAR mutations.</p>
<p>Reviewer #4: Satisfied with the manuscript as edited. Again, it is an important contribution to the literature as I stated in my initial review, though there are not major new insights here. Addition of the PFC data at least provides some additional evidence for more general deficits.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pbio.3000717.r005">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717.r005</article-id>
<title-group>
<article-title>Author response to Decision Letter 1</article-title>
</title-group>
<related-article ext-link-type="doi" id="rel-obj005" related-article-type="editor-report" xlink:href="10.1371/journal.pbio.3000717"></related-article>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">8 Apr 2020</named-content>
</p>
<supplementary-material content-type="local-data" id="pbio.3000717.s019">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response to reviewers Shin et al.docx</named-content></p>
</caption>
<media xlink:href="pbio.3000717.s019.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pbio.3000717.r006">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pbio.3000717.r006</article-id>
<title-group>
<article-title>Decision Letter 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gasque</surname>
<given-names>Gabriel</given-names>
</name>
<role>Senior Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-statement>© 2020 Gabriel Gasque</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Gabriel Gasque</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-article ext-link-type="doi" id="rel-obj006" related-article-type="reviewed-article" xlink:href="10.1371/journal.pbio.3000717"></related-article>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">15 Apr 2020</named-content>
</p>
<p>Dear Dr Kim,</p>
<p>On behalf of my colleagues and the Academic Editor, Thomas C Südhof, I am pleased to inform you that we will be delighted to publish your Research Article in PLOS Biology. </p>
<p>The files will now enter our production system. You will receive a copyedited version of the manuscript, along with your figures for a final review. You will be given two business days to review and approve the copyedit. Then, within a week, you will receive a PDF proof of your typeset article. You will have two days to review the PDF and make any final corrections. If there is a chance that you'll be unavailable during the copy editing/proof review period, please provide us with contact details of one of the other authors whom you nominate to handle these stages on your behalf. This will ensure that any requested corrections reach the production department in time for publication.</p>
<p>Early Version</p>
<p>The version of your manuscript submitted at the copyedit stage will be posted online ahead of the final proof version, unless you have already opted out of the process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p>
<p>PRESS </p>
<p>We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with <email>biologypress@plos.org</email>. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.</p>
<p>We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit <ext-link ext-link-type="uri" xlink:href="http://www.plos.org/about/media-inquiries/embargo-policy/">http://www.plos.org/about/media-inquiries/embargo-policy/</ext-link>.</p>
<p>Thank you again for submitting your manuscript to PLOS Biology and for your support of Open Access publishing. Please do not hesitate to contact me if I can provide any assistance during the production process.</p>
<p>Kind regards,</p>
<p>Vita Usova</p>
<p>Publication Editor, </p>
<p>PLOS Biology</p>
<p>on behalf of</p>
<p>Gabriel Gasque,</p>
<p>Senior Editor</p>
<p>PLOS Biology</p>
</body>
</sub-article>
</article>
</pmc-articleset>